6,7-dihydro-5h-pyrrolo[1,2-a]imidazole derivatives and production method and use thereof
Patent Information
- Application Number
- TW114113083
- Authority / Receiving Office
- TW · TW
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2025-01-02
- Filing Date
- 2025-04-07
- Publication Date
- 2026-11-11
- Estimated Expiration
- 2045-04-06
Abstract
Description
[Technical Field]
[0001] This invention relates to a 6,7-dihydro-5H-pyrrolo[1,2-a]imidazolium derivative, its preparation method, pharmaceutical compositions containing the derivative, and its use as a therapeutic agent, particularly as a Kv1.3 inhibitor. [Previous Technology]
[0002] Ion channels are proteins located within the cell membrane that selectively control the transmembrane ion flow (such as potassium, sodium, and calcium ions), thereby creating a concentration gradient between the intracellular components of the cell and the surrounding extracellular fluid. Since ion concentration directly participates in the electrical activity of excitable cells, ion channels can significantly control the electrical characteristics and state of cells. Ion channels that can open and close are called "gated." Voltage-gated channels are found in neurons, muscle cells, and non-excitable cells such as lymphocytes. They open and close in response to changes in the charge across the plasma membrane, playing a crucial role in cell communication, signal transduction pathways, overall tissue homeostasis, and the function of various organs.
[0003] Potassium ions are one of the main cations in the body, playing an important role in maintaining cell membrane potential and playing an indispensable role in cell proliferation, activation, and apoptosis. The Kv1.3 channel is a member of the voltage-gated potassium channel (Kv) family, encoded by the KCNA3 gene at position 1p13.3 on human chromosome 1. It consists of four similar subunits, each containing a main body composed of six transmembrane structural elements (S1-S6), and N-terminals and C-terminals connected to S1 and S6, respectively. The transmembrane structural elements (S1-S4) constitute the voltage-sensitive region of the channel, while the S5-S6 subunits and the S5-S6 linker fragments (P-loops) embedded in the membrane aggregate to form the channel pore size. Each S4 in the voltage-sensitive region contains abundant positive charges, which are essential for the channel to respond to cell membrane depolarization voltages.
[0004] The Kv1.3 channel was first discovered in human T lymphocytes, and it is also expressed in the immune system, central nervous system, and vascular smooth muscle cells. Kv1.3 plays an important role in regulating resting membrane potential, apoptosis, cell volume regulation, and the activation and proliferation of immune cells. In T cells, cell membrane depolarization leads to the release of Ca2+ into the cell via the release-activated Ca2+ channel (CRAC), resulting in an increase in intracellular Ca2+ concentration and cell membrane depolarization. This mediates the initiation of downstream signaling pathways by calmodulin and other intracellular calmodulin, increasing the expression of Kv1.3 on the cell membrane. This leads to the efflux of intracellular potassium ions, thus maintaining osmotic pressure balance between the inside and outside of the cell. This is an essential condition for the transcription-dependent steps in T cell activation. The Kv1.3 potassium channel is key to the sustained activation of effector T cells. In microglia, Kv1.3 is involved in the killing of neurons during acute respiratory burst neuroinflammation. In dendritic cells, Kv1.3, along with Kv1.5, participates in the secretion of inflammatory cytokines. Because Kv1.3 plays these crucial roles, it is associated with many autoimmune diseases, such as rheumatoid arthritis, psoriasis, systemic lupus erythematosus, atopic dermatitis, ulcerative colitis, Crohn's disease, type 1 diabetes, obesity, hypertension, transplant rejection, multiple sclerosis, periodontitis, and chronic kidney disease.
[0005] Studies have shown that selectively inhibiting the Kv1.3 channel may achieve the goal of selectively inhibiting the initiation process of effector T cells, providing a new approach for the treatment of autoimmune diseases related to effector T cells. Kv1.3 has thus become a novel target protein for the treatment of autoimmune diseases. In addition, Kv1.3 is also involved in neurotoxicity and the development of cancer; abnormal expression of Kv1.3 has been detected in various tumor cells, including breast cancer, prostate cancer, ovarian cancer, and microglia. Experiments have shown that inhibiting Kv1.3 activity can induce apoptosis in tumor cells. Therefore, drugs targeting Kv1.3 have significant clinical value.
[0006] There are no drugs on the market that target Kv1.3, and there is still a lack of effective treatments for autoimmune diseases, which are seriously threatening human health. There is still a huge unmet clinical need. [Summary of the Invention]
[0007] To address the above-mentioned technical problems, the present invention provides a 6,7-dihydro-5H-pyrrolo[1,2-a]imidazolium derivative of general formula (I) or its stereoisomers, tautomers, deuterated derivatives or pharmaceutically acceptable salts thereof: wherein: L is selected from bonds, -C(RaaRbb)- and -C(=O)-; Raa and Rbb are each independently selected from hydrogen atoms, hydroxyl groups and methyl groups; R1 is selected from hydrogen atoms and C1-6 alkyl groups; R2, R3, R4 and R5 are each independently selected from hydrogen atoms, deuterium atoms, halogens, cyano groups, C1-6 alkyl groups, C1-6 alkoxy groups, C2-6 alkenyl groups, C2-6 alkynyl groups, C3-6 cycloalkyl groups, halogenated C3-6 cycloalkyl groups and halogenated C1-6 alkyl groups; Ra is selected from hydrogen atom, C1-6 alkyl, C2-6 alkenyl or C2-6 alkynyl, wherein the C1-6 alkyl, C2-6 alkenyl or C2-6 alkynyl is optionally further substituted by one or more substituents selected from deuterium atom, hydroxyl, halogen, cyano, amino, halo-C1-6 alkyl, halo-C1-6 alkoxy and SF5; Rb, Rc, Rd and Re are each independently selected from hydrogen atom, halogen, C1-6 alkyl, C1-6 alkoxy, halo-C1-6 alkyl and halo-C1-6 alkoxy; or, Rb and Rc, Rd and Re are each independently formed with the same carbon atom to which they are attached into a -C(=O)- or C3-6 cycloalkyl group, wherein the C3-6 cycloalkyl group is optionally further substituted by one or more substituents selected from deuterium atom, hydroxyl, halogen, cyano, amino, halo-C1-6 alkyl, halo-C1-6 alkoxy and SF5. Alternatively, Ra and Rb, Ra and Rd, each independently together with the carbon atom to which they are attached, form a C3-6 cycloalkyl group, wherein the C3-6 cycloalkyl group is optionally further substituted by one or more substituents selected from deuterium, hydroxyl, halogen, cyano, amino, C1-6 alkyl, C1-6 alkoxy, halo-C1-6 alkyl, halo-C1-6 alkoxy, and SF5; RB is selected from hydrogen, hydroxyl, halogen, cyano, amino, SF5, C1-6 alkoxy, and halo-C1-6 alkoxy. RA is selected from hydrogen atom, hydroxyl group, C1-6 alkyl, C2-6 alkenyl, C2-6 ynyl, C3-6 cycloalkyl, 3-12 membered heterocyclic group, C6-10 aryl, 5-6 membered heteroaryl, 6-10 membered fused ring, SF5, -OR6, -OC(=O)R6, -C(=O)R6, -NR7C(=O)R8, -NR7C(=O)OR8, -NR7R8, -C(=O)NR7R8, -S(=O)rNR7R8 and -S(=O)rR5; wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 ynyl, C3-6 cycloalkyl, 3-12 membered heterocyclic group, C6-10 aryl, 5-6 membered heteroaryl, and 6-10 membered fused ring may optionally be further substituted by one or more RAAs;RAAs may be the same or different, and are each independently selected from hydroxyl, halogen, nitro, cyano, C1-6 alkyl, C1-6 alkoxy, C3-6 cycloalkyl, 3-12 heterocyclic, phenyl, 5-6 heteroaryl, -OR9, =O, -C(=O)R9, -S(=O)rR9, -C(=O)OR9, -OC(=O)R9, -NR10R11, -C(=O)NR10R11, -SO2NR10R11, -NR10C(=O)R11 and -NR10C(=O)OR11; wherein the C1-6 alkyl, C1-6 alkoxy, C3-6 cycloalkyl, 3-12 heterocyclic, phenyl or 5 The -6-membered heteroaryl group may be further substituted by one or more substituents selected from hydroxyl, halogen, nitro, cyano, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C3-6 cycloalkyl, 3-12-membered heterocyclic, phenyl, 5-6-membered heteroaryl, =O, -S(=O)rR9, -S(=O)(=NR10)R11, -C(=O)R9, -C(=O)OR9, -OC(=O)R9, -NR10R11, -C(=O)NR10R11, -SO2NR10R11, -NR10C(=O)R11 and -NR10C(=O)OR11; or, the two RAAs together with the same carbon atom to which they are attached form a -C(=O)-; Alternatively, the two RAAs together with the same carbon atom to which they are attached form a C3-6 cycloalkyl or 3-12 heterocyclic group; wherein the C3-6 cycloalkyl or 3-12 heterocyclic group is optionally further substituted by one or more substituents selected from hydroxyl, halogen, nitro, cyano, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C3-6 cycloalkyl, 3-12 heterocyclic group, phenyl, 5-6 heteroaryl, =O, -S(=O)rR9, -S(=O)(=NR10)R11, -C(=O)R9, -C(=O)OR9, -OC(=O)R9, -NR10R11, -C(=O)NR10R11, -SO2NR10R11, -NR10C(=O)R11 and -NR10C(=O)OR11; R6 is independently selected from hydrogen atoms, alkyl, cycloalkyl, heterocyclic, aryl, and heteroaryl, wherein the alkyl, cycloalkyl, heterocyclic, aryl, or heteroaryl group is optionally further substituted by one or more substituents selected from hydroxyl, halogen, nitro, cyano, alkyl, alkoxy, haloalkyl, haloalkoxy, cycloalkyl, heterocyclic, aryl, heteroaryl, =O, -C(=O)R9, -C(=O)OR9, -OC(=O)R9, -NR10R11, -C(=O)NR10R11, -SO2NR10R11, -NR10C(=O)R11, and -NR10C(=O)OR11;R7 and R8 are each independently selected from hydrogen atoms, hydroxyl groups, alkyl groups, alkoxy groups, cycloalkyl groups, heterocyclic groups, aryl groups, and heteroaryl groups, wherein the alkyl, alkoxy, cycloalkyl, heterocyclic, aryl, or heteroaryl group is optionally further substituted by one or more substituents selected from hydroxyl, halogen, nitro, cyano, alkyl, alkoxy, cycloalkyl, heterocyclic, aryl, heteroaryl, =O, -C(=O)R9, -C(=O)OR9, -OC(=O)R9, -NR10R11, -C(=O)NR10R11, -SO2NR10R11, -NR10C(=O)R11, and -NR10C(=O)OR11; Alternatively, R7 and R8 together with the atoms they are connected to form a 3- to 12-membered heterocyclic group, wherein the 3- to 12-membered heterocyclic group contains one or more N, O or S(O)r, and the 3- to 12-membered heterocyclic group is optionally further substituted by one or more substituents selected from hydroxyl, halogen, nitro, cyano, alkyl, alkoxy, cycloalkyl, heterocyclic, aryl, heteroaryl, =O, -C(=O)R9, -C(=O)OR9, -OC(=O)R9, -NR10R11, -C(=O)NR10R11, -SO2NR10R11, -NR10C(=O)R11 and -NR10C(=O)OR11; R9, R10, and R11 are each independently selected from hydrogen atoms, alkyl, amino, cycloalkyl, heterocyclic, aryl, and heteroaryl groups, wherein the alkyl, cycloalkyl, heterocyclic, aryl, or heteroaryl group is optionally further substituted by one or more substituents selected from hydroxyl, halogen, nitro, amino, cyano, alkyl, alkoxy, cycloalkyl, heterocyclic, aryl, heteroaryl, carboxyl, and carboxylic acid ester groups; r is each independently 0, 1, or 2; provided that compounds of general formula (I) do not include the following structures: . ;
[0008] A preferred embodiment of the present invention is a 6,7-dihydro-5H-pyrrolo[1,2-a]imidazolium derivative of general formula (I) or its stereoisomers, tautomers, deuterated derivatives or pharmaceutically acceptable salts thereof, wherein R1 is a hydrogen atom.
[0009] A preferred embodiment of the present invention is a 6,7-dihydro-5H-pyrrolo[1,2-a]imidazolium derivative of general formula (I) or its stereoisomers, tautomers, deuterated derivatives or pharmaceutically acceptable salts thereof, wherein RB is a hydrogen atom.
[0010] A preferred embodiment of the present invention is a 6,7-dihydro-5H-pyrrolo[1,2-a]imidazolium derivative or its stereoisomers, tautomers, deuterated derivatives or pharmaceutically acceptable salts thereof, represented by general formula (I), which is a compound of general formula (II) or its stereoisomers, tautomers, deuterated derivatives or pharmaceutically acceptable salts thereof: wherein: R2 is selected from hydrogen atoms and halogens; the halogen is preferably chlorine; R3 is selected from C1-4 alkyl groups and halogens, the halogen is preferably chlorine, and the C1-4 alkyl group is preferably methyl; R4 is selected from hydrogen atoms, C1-4 alkyl groups and halogens, the halogen is preferably chlorine, and the C1-4 alkyl group is preferably methyl; L, Ra, Rb, Rc, Rd, Re, RA, R5 and RB are defined as in general formula (I).
[0011] A preferred embodiment of the present invention is a 6,7-dihydro-5H-pyrrolo[1,2-a]imidazolium derivative or its stereoisomers, tautomers, deuterated derivatives or pharmaceutically acceptable salts thereof, represented by general formula (I) or (II), which is a compound of general formula (III-1) or (III-2) or its stereoisomers, tautomers, deuterated derivatives or pharmaceutically acceptable salts thereof: wherein: R3 is selected from methyl and chlorine; R4 is selected from methyl and chlorine; R5 is selected from hydrogen atom, deuterium atom, halogen, cyano, C1-6 alkyl, C2-6 alkynyl and C1-6 alkoxy; L, Ra, Rb, Rc, Rd, Re, RA and RB are defined as in general formula (I).
[0012] A preferred embodiment of the present invention is a 6,7-dihydro-5H-pyrrolo[1,2-a]imidazolium derivative or its stereoisomers, tautomers, deuterated derivatives or pharmaceutically acceptable salts thereof, represented by general formula (I), (II), (III-1) or (III-2), wherein Rb, Rc, Rd, Re are hydrogen atoms, and Ra is selected from hydrogen atoms, C1-6 alkyl or C2-6 alkenyl, wherein the C1-6 alkyl or C2-6 alkenyl is optionally further substituted by one or more atoms selected from deuterium atoms or halogens.
[0013] A preferred embodiment of the present invention is a 6,7-dihydro-5H-pyrrolo[1,2-a]imidazolium derivative or its stereoisomers, tautomers, deuterated derivatives or pharmaceutically acceptable salts thereof, represented by general formula (I), (II), (III-1) or (III-2), wherein Ra is selected from hydrogen atoms, methyl, deuterated methyl, ethyl or vinyl.
[0014] A preferred embodiment of the present invention is a 6,7-dihydro-5H-pyrrolo[1,2-a]imidazolium derivative or its stereoisomers, tautomers, deuterated derivatives or pharmaceutically acceptable salts represented by general formula (I), (II), (III-1) or (III-2), wherein Rc, Rd, and Re are hydrogen atoms, and Ra and Rb together with the carbon atoms to which they are attached form a cyclopropyl group.
[0015] A preferred embodiment of the present invention is a 6,7-dihydro-5H-pyrrolo[1,2-a]imidazolium derivative or its stereoisomers, tautomers, deuterated derivatives or pharmaceutically acceptable salts of general formula (I), (II), (III-1) or (III-2), which is a compound of general formula (IV-1), (IV-2), (IV-3) or (IV-4) or its stereoisomers, tautomers, deuterated derivatives or pharmaceutically acceptable salts thereof: wherein: R3 is each independently selected from methyl and chlorine; R4 is each independently selected from methyl and chlorine; R5 is selected from hydrogen, deuterium, fluorine or chlorine, preferably from hydrogen, fluorine and chlorine; Ra is selected from hydrogen, methyl, deuterated methyl, ethyl and vinyl; L and RA are defined as described in claim 1.
[0016] A preferred embodiment of the present invention is a 6,7-dihydro-5H-pyrrolo[1,2-a]imidazolium derivative or its stereoisomers, tautomers, deuterated derivatives or pharmaceutically acceptable salts represented by general formula (I), (II), (III-1), (III-2), (IV-1), (IV-2), (IV-3) or (IV-4), wherein L is selected from bond, -CH2-, -C(CH3)2-, -C(CH3)(OH)- or -C(=O)-.
[0017] A preferred embodiment of the present invention is a 6,7-dihydro-5H-pyrrolo[1,2-a]imidazolium derivative of general formula (I), (II), (III-1), (III-2), (IV-1), (IV-2), (IV-3) or (IV-4) or a stereoisomer, tautomer, deuterated derivative or pharmaceutically acceptable salt thereof, wherein RA is selected from hydroxyl, amino, phenyl, C1-6 alkyl, C2-6 alkenyl, 3-12 heterocyclic or 5-6 heteroaryl, wherein the phenyl, C1-6 alkyl, C2-6 alkenyl, 3-12 heterocyclic or 5-6 heteroaryl is optionally further substituted by one or more RAAs; the RAAs are the same or different, each independently selected from halogen, hydroxyl, amino, C1-6 alkyl, halo-C1-6 alkyl and hydroxy-C1-6 alkyl; or, two RAAs together with the same carbon atom to which they are attached form a -C(=O)-; Alternatively, two RAAs together with the same carbon atom they are attached to form a C3-6 cycloalkyl, 3-12 membered heterocyclic group.
[0018] A preferred embodiment of the present invention is a 6,7-dihydro-5H-pyrrolo[1,2-a]imidazolium derivative or a stereoisomer, tautomer, deuterated derivative or pharmaceutically acceptable salt thereof represented by general formula (I), (II), (III-1), (III-2), (IV-1), (IV-2), (IV-3) or (IV-4), wherein the group is selected from the following groups: ethyl, vinyl, and, wherein the wavy line indicates the position attached to the compound.
[0019] In a preferred embodiment of the present invention, the compounds of the general formula are selected from: Compound numbering structure name Example 1 3,4-dichloro-2-(2-(2-hydroxypropan-2-yl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-6-yl)phenol 3,4-Dichloro-2-(2-(2-hydroxypropyl-2-yl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-6-yl)phenol Example 2 (S)-3,4-dichloro-2-(2-(2-hydroxypropan-2-yl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-6-yl)phenol (S)-3,4-dichloro-2-(2-(2-hydroxypropyl-2-yl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-6-yl)phenol Example 3 (R)-3,4-dichloro-2-(2-(2-hydroxypropan-2-yl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-6-yl)phenol (R)-3,4-dichloro-2-(2-(2-hydroxypropyl-2-yl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-6-yl)phenol Example 4 1-((6-(2,3-dichloro-6-hydroxyphenyl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-2-yl)methyl)-4-methylpiperidin-4-ol 1-((6-(2,3-dichloro-6-hydroxyphenyl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-2-yl)methyl)-4-methylguanidine-4-ol Example 5 1-((6-(2,3-dichloro-6-hydroxyphenyl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-2-yl)methyl)-3-methylazetidin-3-ol 1-((6-(2,3-dichloro-6-hydroxyphenyl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-2-yl)methyl)-3-methylazacyclobutane-3-ol Example 6 1-((6-(2,3-dichloro-6-hydroxyphenyl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-2-yl)methyl)-3-(trifluoromethyl)azetidin-3-ol 1-((6-(2,3-dichloro-6-hydroxyphenyl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-2-yl)methyl)-3-(trifluoromethyl)azacyclobutane-3-ol Example 7 1-((6-(2,3-dichloro-6-hydroxyphenyl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-2-yl)methyl)pyrrolidin-3-ol 1-((6-(2,3-dichloro-6-hydroxyphenyl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-2-yl)methyl)pyrrolidin-3-ol Example 8 1-((6-(2,3-dichloro-6-hydroxyphenyl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-2-yl)methyl)-3-methylpyrrolidin-3-ol 1-((6-(2,3-dichloro-6-hydroxyphenyl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-2-yl)methyl)-3-methylpyrrolidin-3-ol Example 9 1-((6-(2,3-dichloro-6-hydroxyphenyl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-2-yl)methyl)-3-methylpiperidin-3-ol 1-((6-(2,3-dichloro-6-hydroxyphenyl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-2-yl)methyll)-3-methylpiperidin-3-ol Example 10 1-((6-(2,3-dichloro-6-hydroxyphenyl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-2-yl)methyl)piperidin-4-ol 1-((6-(2,3-dichloro-6-hydroxyphenyl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-2-yl)methyl)piperidine-4-ol Example 11 1-((6-(2,3-dichloro-6-hydroxyphenyl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-2-yl)methyl)azetidin-3-ol 1-((6-(2,3-dichloro-6-hydroxyphenyl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-2-yl)methyl)azacyclobutane-3-ol Example 12 2-((6-(2,3-dichloro-6-hydroxyphenyl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-2-yl)methyl)-6-methyl-2-azaspiro[3.3]heptan-6-ol 2-((6-(2,3-dichloro-6-hydroxyphenyl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-2-yl)methyl)-6-methyl-2-azaspiro[3,3]hepta-6-ol Example 13 2-((6-(2,3-dichloro-6-hydroxyphenyl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-2-yl)methyl)-2-azaspiro[3.3]heptan-6-ol 2-((6-(2,3-dichloro-6-hydroxyphenyl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-2-yl)methyl)-2-azaspiro[3,3]hepta-6-ol Example 14 3,4,6-trichloro-2-(2-(2-hydroxypropan-2-yl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-6-yl)phenol 3,4,6-Trichloro-2-(2-(2-hydroxypropyl-2-yl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-6-yl)phenol Example 15 3,4-dichloro-6-fluoro-2-(2-(2-hydroxypropan-2-yl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-6-yl)phenol 3,4-Dichloro-6-fluoro-2-(2-(2-hydroxypropyl-2-yl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-6-yl)phenol Example 16 3,4-dichloro-2-(2-(2-hydroxypropan-2-yl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-6-yl)phen-6-d-ol 3,4-Dichloro-2-(2-(2-hydroxypropyl-2-yl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-6-yl)benzene-6-deuterol Example 17 3,4-dichloro-2-fluoro-6-(2-(2-hydroxypropan-2-yl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-6-yl)phenol 3,4-Dichloro-2-fluoro-6-(2-(2-hydroxypropyl-2-yl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-6-yl)phenol Example 18 4,5-dichloro-2-(2-(2-hydroxypropan-2-yl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-6-yl)phen-6-d-ol 4,5-Dichloro-2-(2-(2-hydroxypropyl-2-yl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-6-yl)benzene-6-deuterol Example 19 3,4-dichloro-2-(2-(pyrrolidin-3-yl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-6-yl)phenol 3,4-Dichloro-2-(2-(pyrrolidine-3-yl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-6-yl)phenol Example 20 3,4-dichloro-2-(2-ethyl-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-6-yl)phenol 3,4-Dichloro-2-(2-ethyl-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-6-yl)phenol Example 21 2-(2-(1H-pyrazol-4-yl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-6-yl)-3,4-dichlorophenol 2-(2-(1H-pyrazol-4-yl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-6-yl)-3,4-dichlorophenol Example 22 3,4-dichloro-2-(2-(2-hydroxypropan-2-yl)-6-methyl-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-6-yl)phenol 3,4-Dichloro-2-(2-(2-hydroxypropyl-2-yl)-6-methyl-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-6-yl)phenol Example 23 3,4-dichloro-2-(2-vinyl-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-6-yl)phenol 3,4-Dichloro-2-(2-vinyl-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-6-yl)phenol Example 24 3,4-dichloro-2-(2-(4-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-6-yl)phenol 3,4-Dichloro-2-(2-(4-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-6-yl)phenol Example 25 3,4-dichloro-2-(2-(pyridin-4-yl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-6-yl)phenol 3,4-Dichloro-2-(2-(pyridin-4-yl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-6-yl)phenol Example 26 3,4-dichloro-2-(2-(trifluoromethyl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-6-yl)phenol 3,4-Dichloro-2-(2-(trifluoromethyl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-6-yl)phenol Example 27 2-(2-(1H-pyrazol-4-yl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-6-yl)-3,4,6-trichlorophenol 2-(2-(1H-pyrazol-4-yl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-6-yl)-3,4,6-trichlorophenol Example 28 3,4-dichloro-2-(2-(prop-1-en-2-yl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-6-yl)phenol 3,4-Dichloro-2-(2-(prop-1-en-2-yl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-6-yl)phenol Example 29 3,4-dichloro-2-(2-(cyclobutylidenemethyl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-6-yl)phenol 3,4-Dichloro-2-(2-(cyclobutylmethyl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-6-yl)phenol Example 30 3,4-dichloro-2-(2-(piperidin-4-ylidenemethyl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-6-yl)phenol 3,4-Dichloro-2-(2-(piperidin-4-methylenemethyl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-6-yl)phenol Example 31 3,4-dichloro-6-fluoro-2-(2-(prop-1-en-2-yl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-6-yl)phenol 3,4-Dichloro-6-fluoro-2-(2-(prop-1-en-2-yl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-6-yl)phenol Example 32 3,4-dichloro-6-fluoro-2-(2-(2-hydroxypropan-2-yl)-6-methyl-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-6-yl)phenol 3,4-Dichloro-6-fluoro-2-(2-(2-hydroxypropyl-2-yl)-6-methyl-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-6-yl)phenol
[0020] or its stereoisomers, tautomers, or pharmaceutically usable salts. Note: In case of any discrepancy between the drawn structure and the given name of the structure, the drawn structure shall prevail.
[0021] Furthermore, the present invention provides a pharmaceutical composition comprising an effective dose of a compound of general formula (I), (II), (III-1), (III-2), (IV-1), (IV-2), (IV-3) or (IV-4) or a stereoisomer, tautomer, deuterated product or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
[0022] The present invention provides the use of a compound of general formula (I), (II), (III-1), (III-2), (IV-1), (IV-2), (IV-3) or (IV-4) or its stereoisomer, tautomer, deuterated product or pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, in the preparation of a Kv1.3 inhibitor.
[0023] The present invention also provides the use of a compound of formula (I), (II), (III-1), (III-2), (IV-1), (IV-2), (IV-3) or (IV-4) or a stereoisomer, tautomer, deuterated product or a pharmaceutically usable salt thereof, or a pharmaceutical composition thereof, in the preparation of a medicament for treating diseases mediated by Kv1.3, wherein the Kv1.3-mediated disease is preferably an autoimmune disease; wherein the Kv1.3-mediated disease is selected from rheumatoid arthritis, psoriasis, systemic lupus erythematosus, atopic dermatitis, ulcerative colitis, Crohn's disease, type I diabetes, obesity, hypertension, transplant rejection, multiple sclerosis, periodontitis and chronic kidney disease.
[0024] The present invention further provides the use of a compound of formula (I), (II), (III-1), (III-2), (IV-1), (IV-2), (IV-3) or (IV-4) or its stereoisomer, tautomer, deuterated product or its pharmaceutically usable salt, or a pharmaceutical composition thereof in the preparation of a medicament for treating cancer.
[0025] This invention provides the use of compounds of general formulas (I), (II), (III-1), (III-2), (IV-1), (IV-2), (IV-3), or (IV-4), or their stereoisomers, tautomers, deuterated derivatives, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof, in the preparation of medicaments for treating rheumatoid arthritis, psoriasis, systemic lupus erythematosus, atopic dermatitis, ulcerative colitis, Crohn's disease, type I diabetes, obesity, hypertension, transplant rejection, multiple sclerosis, periodontitis, or chronic kidney disease. Detailed Description of the Invention
[0026] Unless otherwise stated, some terms used in the specification and claims of this invention are defined as follows: “alkyl” when used as a group or part of a group refers to a C1-C20 straight-chain or branched aliphatic hydrocarbon group. Preferably, it is a C1-C10 alkyl group, more preferably a C1-C6 alkyl group. Examples of alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, etc. The alkyl group may be substituted or unsubstituted.
[0027] “Cycloalkyl” refers to a non-aromatic cyclic alkyl group in which one or more cyclic atoms are carbon atoms, and the ring contains 0, 1, or more double bonds, including monocyclic, polycyclic, fused, bridged, and spirocyclic rings, preferably having a 3- to 7-membered monocyclic ring or a 4- to 18-membered bicyclic or tricyclic ring. Examples of “cycloalkyl” include, but are not limited to, cyclopropyl, cyclopentyl, and cyclobutyl. Cycloalkyl groups can be substituted or unsubstituted.
[0028] “Spirocycloalkyl” refers to a polycyclic group consisting of 5 to 18 quinones, two or more cyclic structures, wherein the monocyclic rings share a carbon atom (called a spiro atom) with each other, and containing 0, 1 or more double bonds within the rings, but none of the rings having fully conjugated π electrons. Preferably, it is 6 to 14 quinones, more preferably 7 to 10 quinones. Spirocycloalkyl is classified into monospiro, bispiro, or polyspirocycloalkyl according to the number of spiro atoms shared between the rings, preferably monospiro and bispirocycloalkyl, preferably 4 / 5, 4 / 6, 5 / 5 or 5 / 6 quinones. Non-limiting examples of “spirocycloalkyl” include, but are not limited to: spiro[4.5]decyl, spiro[4.4]nonyl, spiro[3.5]nonyl, spiro[2.4]heptyl.
[0029] “Fused cycloalkyl” refers to a 4- to 18-membered, all-carbon polycyclic group containing two or more cyclic structures sharing a pair of carbon atoms, wherein one or more rings may contain 0, 1 or more double bonds, but none of the rings have fully conjugated π electrons, preferably a 6- to 14-membered aromatic system, more preferably a 7- to 10-membered system. Depending on the number of constituent rings, it can be classified as bicyclic, tricyclic, tetracyclic or polycyclic fused cycloalkyl, preferably bicyclic or tricyclic, more preferably 5-membered / 5-membered or 5-membered / 6-membered bicyclic fused cycloalkyl. Non-limiting examples of “fused cycloalkyl” include, but are not limited to: bicyclo[3.1.0]hexyl, bicyclo[3.2.0]hept-1-enyl, bicyclo[3.2.0]heptyl, decahydronaphthyl, tetradecahydrophenanthrene.
[0030] “Bridged cycloalkyl” refers to an aromatic system consisting of 5 to 18 members, containing two or more cyclic structures, sharing two non-directly connected carbon atoms, and one or more rings may contain 0, 1, or more double bonds, but none of the rings has fully conjugated π electrons. It is preferably 6 to 14 members, more preferably 7 to 10 members. Depending on the number of constituent rings, it can be classified as bicyclic, tricyclic, tetracyclic, or polycyclic bridged cycloalkyl, preferably bicyclic, tricyclic, or tetracyclic, and more preferably bicyclic or tricyclic. Non-limiting examples of “bridged cycloalkyl” include, but are not limited to: (1s,4s)-bicyclo[2.2.1]heptyl, bicyclo[3.2.1]octyl, (1s,5s)-bicyclo[3.3.1]nonyl, bicyclo[2.2.2]octyl, and (1r,5r)-bicyclo[3.3.2]decyl.
[0031] The terms "heterocyclic group," "heterocyclic alkyl group," "heterocyclic," or "heterocyclic" are used interchangeably in this application and all refer to non-aromatic heterocyclic groups, including monocyclic, polycyclic, fused-ring, bridged-ring, and spirocyclic groups, which may contain one or more double bonds, but none of the rings have fully conjugated π electrons in an aromatic system, wherein one, two, three, or four cyclic atoms are selected from nitrogen, oxygen, or S(O)r (where r is selected from 0, 1, or 2) heteroatoms. Preferably, it has a 3- to 7-membered monocyclic or a 4- to 18-membered bicyclic or tricyclic ring.
[0032] Examples of “heterocyclic groups” include, but are not limited to, morpholino, oxetane, azabolo, thiomorpholino, tetrahydrofurano, tetrahydropyrano, 1,1-dioxo-thiomorpholino, piridino, 2-oxo-piridino, pyrrolidinyl, 2-oxo-pyrrolidinyl, piridin-2-one, 8-oxa-3-aza-bicyclo[3.2.1]octyl, piridinyl, hexahydropyrimidine. Heterocyclic groups may be substituted or unsubstituted.
[0033] "Spirocycloalkyl" refers to a polycyclic group with 5 to 18 members, two or more cyclic structures, where the monocyclic rings share an atom with each other, and the rings may contain one or more double bonds, but none of the rings have fully conjugated π electrons. One or more ring atoms are selected from nitrogen, oxygen, or S(O)r (where r is selected from 0, 1, or 2) heteroatoms, and the remaining ring atoms are carbon. Preferably, it is 6 to 14 members, more preferably 7 to 10 members. Spirocycloalkyl groups are classified into monospirocycloalkyl, bispirocycloalkyl, or polyspirocycloalkyl groups according to the number of spiro atoms shared between the rings. Preferably, it is monospirocycloalkyl and bispirocycloalkyl, more preferably 3 / 6, 4 / 4, 4 / 5, 4 / 6, 5 / 5, 5 / 6, or 6 / 6 monospirocycloalkyl groups. Non-limiting embodiments of "spirocyclocyclic groups" include, but are not limited to: 1,7-dioxaspiro[4.5]decyl, 2-oxa-7-azaspiro[4.4]nonyl, 7-oxaspiro[3.5]nonyl, 5-oxaspiro[2.4]heptyl, etc.
[0034] "Fused heterocyclic group" refers to a polycyclic group containing two or more ring structures sharing a pair of atoms. One or more rings may contain 0, 1 or more double bonds, but none of the rings has fully conjugated π electrons. One or more ring atoms are selected from nitrogen, oxygen or S(O)r (where r is selected from 0, 1 or 2) heteroatoms, and the remaining ring atoms are carbon. Preferably, it is 6 to 14-membered, more preferably 7 to 10-membered. According to the number of constituent rings, it can be divided into bicyclic, tricyclic, tetracyclic or polycyclic fused heterocyclic groups, preferably bicyclic or tricyclic, more preferably 5-membered / 5-membered or 5-membered / 6-membered bicyclic fused heterocyclic groups. Non-limiting examples of "fused heterocyclic group" include, but are not limited to: octahydropyrrolo[3,4-c]pyrrol, octahydro-1H-isoindolyl, 3-azabicyclo[3.1.0]hexyl, octahydrobenzo[b][1,4]dioxin.
[0035] "Bridged heterocyclic group" refers to a 5- to 18-membered polycyclic group containing two or more ring structures that share two atoms that are not directly connected. One or more rings may contain 0, 1, or more double bonds, but none of the rings have fully conjugated π electrons in an aromatic system. One or more ring atoms are selected from nitrogen, oxygen, or S(O)r (where r is selected from 0, 1, or 2) heteroatoms, and the remaining ring atoms are carbon. Preferably, it is 6- to 14-membered, more preferably 7- to 10-membered. According to the number of constituent rings, it can be classified as bicyclic, tricyclic, tetracyclic, or polycyclic bridged heterocyclic groups, preferably bicyclic, tricyclic, or tetracyclic, and more preferably bicyclic or tricyclic. Non-limiting embodiments of "bridged heterocyclic group" include, but are not limited to: 2-azabicyclo[2.2.1]heptyl, 2-azabicyclo[2.2.2]octyl, 2-azabicyclo[3.3.2]decyl, etc.
[0036] "Aryl" refers to a carbocyclic aromatic system containing one or two rings, wherein the rings may be connected together in a fused manner. The term "aryl" includes monocyclic or bicyclic aryl groups, such as phenyl, naphthyl, and tetrahydronaphthyl aromatic groups. Preferably, the aryl group is a C6-C10 aryl group, more preferably phenyl and naphthyl, and most preferably naphthyl. The aryl group may be substituted or unsubstituted.
[0037] “Heteroaryl” refers to an aromatic 5- to 6-membered monocyclic or 8- to 10-membered bicyclic ring, which may contain 1 to 4 (1, 2, 3 or 4) atoms selected from nitrogen, oxygen and / or sulfur. Examples of "heteroaryl" compounds include, but are not limited to, furanyl, pyridyl, 2-oxo-1,2-dihydropyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, thiopheneyl, isoxazolyl, oxazolyl, oxadiazolyl, imidazolyl, pyrroleyl, pyrazolyl, triazolyl, tetrazolyl, thiazolyl, isothiazolyl, 1,2,3-thiadiazolyl, benzo[m]dioxacyclopentenyl, benzo[thiophene], benzimidazolyl, indoleyl, isoyindolyl, 1,3-dioxo-isoindolyl, quinolinyl, indoleyl, benzo[isothiazolyl], benzo[oxazolyl], benzo[isothiazolyl], isothiazolyl, 1H-1,2,4-triazolyl, 4H-1,2,4-triazolyl, pyridyl, pyridine-2 (1H)-keto, pyrimidinyl, pyrazin-2(1H)-keto, pyrimidin-4(3H)-keto, pyrimidin-2(1H)-keto, pyridazin-3(2H)-keto, 1H-indolyl, 1H-benzo[d]imidazolyl, 1H-pyrrolo[2,3-c]pyridyl, 3H-imidazo[4,5-c]pyridyl, isoquinolinyl, quinazolinyl, 2H-isoindolyl, furan[3,2-b]pyridyl, furan[2,3-c]pyridyl, thieno[2,3-c]pyridyl, benzofuranyl, benzo[b]thienoyl, 1H-pyrrolo[3,2-b]pyridyl, 2H-pyrrolo[3,4-c]pyridyl, or.
[0038] The heteroaryl group can be substituted or unsubstituted.
[0039] A "fused ring" refers to a polycyclic group in which two or more cyclic structures share a pair of atoms, wherein at least one ring has a fully conjugated π-electron aromatic system, and one or more rings may contain 0, 1, or more double bonds, but at least one ring does not have a fully conjugated π-electron aromatic system, wherein the ring atoms are selected from 0, 1, or more heteroatoms selected from nitrogen, oxygen, or S(O)r (where r is selected from 0, 1, or 2), and the remaining ring atoms are carbon. Fused rings preferably include bicyclic or tricyclic fused rings, wherein bicyclic fused rings are preferably fused rings of aryl or heteroaryl groups with monocyclic heterocyclic groups or monocyclic cycloalkyl groups, preferably 6 to 14 members, more preferably 8 to 10 members. Examples of "fused rings" include, but are not limited to:
[0040] “Alkoxy” refers to a (alkyl-O-) group. Wherein, alkyl is defined in the relevant section of this document. C1-C6 alkoxy groups are preferred. Examples include, but are not limited to: methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, tert-butoxy, etc.
[0041] “Nitro” refers to the -NO2 group.
[0042] “Hydrogen group” refers to the -OH group.
[0043] “Halogen” refers to fluorine, chlorine, bromine and iodine.
[0044] “Amino” refers to -NH2.
[0045] “Cyano” refers to -CN.
[0046] “Benzyl” refers to -CH2-phenyl.
[0047] “Carboxyl group” refers to -C(=O)OH.
[0048] “Carboxylic acid ester group” refers to -C(=O)O-alkyl or -C(=O)O-cycloalkyl, wherein the definitions of alkyl and cycloalkyl are as described above.
[0049] “Hydroalkyl” refers to a hydroxy-substituted alkyl group, wherein the definition of alkyl is as described above.
[0050] “Aminoalkyl” refers to an amino-substituted alkyl group, wherein the definition of alkyl is as described above.
[0051] “Halogenated alkyl” refers to halogen-substituted alkyl, wherein the definition of alkyl is as described above.
[0052] “Halogenated alkoxy” refers to alkoxy groups substituted with halogens, wherein the definition of alkoxy groups is as described above.
[0053] "DMSO" refers to dimethyl monoxide.
[0054] “BOC” refers to tert-butoxycarbonyl.
[0055] “Bn” refers to benzyl.
[0056] “THP” refers to 2-tetrahydropyranyl.
[0057] "TFA" refers to trifluoroacetic acid.
[0058] "FA" Nail acid.
[0059] “Ts” refers to p-toluenesulfonyl.
[0060] “Bn” refers to benzyl.
[0061] “SEM” refers to (trimethylsilicon)ethoxymethyl.
[0062] A "leaving group" is an atom or functional group that breaks off from a larger molecule in a chemical reaction. It is a term used in nucleophilic substitution and elimination reactions. In a nucleophilic substitution reaction, the reactant attacked by the nucleophile is called the substrate, and the atom or group of atoms that breaks off with a pair of electrons from the substrate molecule is called the leaving group. Groups that readily accept electrons and have a strong ability to accept negative charges are good leaving groups. The smaller the pKa of the conjugate acid of the leaving group, the easier it is for the leaving group to break off from other molecules. This is because the smaller the pKa of its conjugate acid, the less likely the leaving group is to combine with other atoms, and the stronger its tendency to exist as an anion (or an electrically neutral leaving group). Common leaving groups include, but are not limited to, halogens, methanesulfonyl groups, -OTs, or -OH.
[0063] "Substituted" refers to one or more hydrogen atoms in a group, preferably up to five, more preferably one, two, or three hydrogen atoms, which are independently substituted by the corresponding number of substituents. It goes without saying that the substituents are only in their possible chemical positions, and those skilled in the art can determine (by experiment or theory) possible or impossible substitutions without much effort. For example, an amino or hydroxyl group with free hydrogen may be unstable when combined with a carbon atom having an unsaturated bond (such as an alkene).
[0064] Unless otherwise specified, “substitution” or “substituted” as used in this specification means that a group can be substituted by one or two or three or more groups selected from the following: alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocyclic, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio, amino, haloalkyl, halocycloalkyl, haloalkoxy, hydroxyalkyl, carboxyl, carboxylic acid ester, fused ring, =O, -OR6, SF5, -OC(=O)R6, -C(=O)R6, -NR7C(=O)R8, -NR7C(=O)OR8, -NR7R8, -C(=O)NR7R8, -S(=O)rNR7R8 or -S(=O)rR5; R6 is independently selected from hydrogen atom, alkyl, cycloalkyl, heterocyclic, aryl or heteroaryl, wherein the alkyl, cycloalkyl, heterocyclic, aryl or heteroaryl is optionally further substituted by one or more substituents selected from hydroxyl, halogen, nitro, cyano, alkyl, alkoxy, haloalkyl, haloalkoxy, cycloalkyl, heterocyclic, aryl, heteroaryl, =O, -C(=O)R9, -C(=O)OR9, -OC(=O)R9, -NR10R11, -C(=O)NR10R11, -SO2NR10R11, -NR10C(=O)R11 and -NR10C(=O)OR11; R7 and R8 are each independently selected from hydrogen atoms, hydroxyl groups, alkyl groups, alkoxy groups, cycloalkyl groups, heterocyclic groups, aryl groups, and heteroaryl groups, wherein the alkyl, alkoxy, cycloalkyl, heterocyclic, aryl, or heteroaryl group is optionally further substituted by one or more substituents selected from hydroxyl, halogen, nitro, cyano, alkyl, alkoxy, cycloalkyl, heterocyclic, aryl, heteroaryl, =O, -C(=O)R9, -C(=O)OR9, -OC(=O)R9, -NR10R11, -C(=O)NR10R11, -SO2NR10R11, -NR10C(=O)R11, and -NR10C(=O)OR11; Alternatively, R7 and R8 together with the atoms they are connected to form a 3- to 12-membered heterocyclic group, wherein the 3- to 12-membered heterocyclic group contains one or more N, O or S(O)r, and the 3- to 12-membered heterocyclic group is optionally further substituted by one or more substituents selected from hydroxyl, halogen, nitro, cyano, alkyl, alkoxy, cycloalkyl, heterocyclic, aryl, heteroaryl, =O, -C(=O)R9, -C(=O)OR9, -OC(=O)R9, -NR10R11, -C(=O)NR10R11, -SO2NR10R11, -NR10C(=O)R11 and -NR10C(=O)OR11;R9, R10, and R11 are each independently selected from hydrogen atoms, alkyl, amino, cycloalkyl, heterocyclic, aryl, and heteroaryl groups, wherein the alkyl, cycloalkyl, heterocyclic, aryl, or heteroaryl group is optionally further substituted by one or more substituents selected from hydroxyl, halogen, nitro, amino, cyano, alkyl, alkoxy, cycloalkyl, heterocyclic, aryl, heteroaryl, carboxyl, and carboxylic acid ester groups; r is each independently 0, 1, or 2.
[0065] The compounds of the present invention may contain asymmetric centers or chiral centers, and thus exist in different stereoisomer forms. It is contemplated that all stereoisomer forms of the compounds of the present invention, including but not limited to diastereomers, enantiomers, atropisomers, and geometric (conformal) isomers and mixtures thereof, such as racemic mixtures, are within the scope of the present invention.
[0066] Unless otherwise indicated, the structure described in this invention also includes all isomers of this structure (e.g., diastereomers, enantiomers, and trans-blocking isomers and geometric (conformal) isomers; for example, R and S configurations of each asymmetric center, (Z) and (E) double bond isomers, and (Z) and (E) conformational isomers). Therefore, individual stereoisomers of the compounds of this invention, as well as mixtures of enantiomers, mixtures of diastereomers, and mixtures of geometric (conformal) isomers, are all within the scope of this invention.
[0067] "Medicinal salts" refer to certain salts of the above-mentioned compounds that retain their original biological activity and are suitable for medicinal use. Medicinal salts of compounds represented by general formula (I) can be metal salts or amine salts formed with suitable acids.
[0068] A “pharmaceutical composition” means a mixture containing one or more of the compounds described herein or their physiologically pharmaceutically acceptable salts or prodrugs, along with other chemical components, such as a physiologically pharmaceutically acceptable carrier. The purpose of a pharmaceutical composition is to facilitate administration to a living organism, thereby promoting the absorption of the active ingredient and the exertment of its biological activity.
Implementation Method
[0070] The following embodiments are used to further describe the present invention, but these embodiments are not intended to limit the scope of the present invention. Embodiments
[0071] Examples provide the preparation and related structural identification data of representative compounds represented by formula (I). It must be noted that the following examples are for illustrative purposes only and not for limiting the invention. ¹H NMR spectra were obtained using a Bruker instrument (400 MHz), and chemical shifts are expressed in ppm. Tetramethylsilane internal standard (0.00 ppm) was used. ¹H NMR representation: s = singlet, d = doublet, t = triplet, m = multiplet, br = broadened, dd = doublet of doublet, dt = doublet of triplet. If coupling constants are provided, their units are Hz.
[0072] Mass spectrometry is obtained by LC / MS instrument, and the ionization method can be electrospray ionization (ESI) or atmospheric pressure chemical ionization (APCI).
[0073] The thin-layer chromatography silica gel plates used are Yantai Huanghai HSGF254 or Qingdao GF254 silica gel plates. The silica gel plates used in thin-layer chromatography (TLC) have a size of 0.15 mm to 0.2 mm, and the size used for thin-layer chromatography separation and purification of products is 0.4 mm to 0.5 mm.
[0074] Column chromatography generally uses Yantai Huanghai silicone 200~300 mesh silicone as a carrier.
[0075] In the following examples, unless otherwise specified, all temperatures are in Celsius. Unless otherwise specified, all starting materials and reagents are commercially available or synthesized according to known methods. Commercially available materials and reagents are used directly without further purification. Unless otherwise specified, they are purchased from manufacturers including but not limited to Aldrich Chemical Company, ABCR GmbH & Co.KG, Acros Organics, Guangzan Chemical Technology Co., Ltd., and Jingyan Chemical Technology Co., Ltd.
[0076] CD3OD: Deuterated methanol.
[0077] CDCl3: Deuterated chloroform.
[0078] DMSO-d 6: Deuterated dimethyl monoxide.
[0079] Argon atmosphere refers to a reaction flask connected to an argon balloon with a volume of approximately 1L.
[0080] Unless otherwise specified in the examples, the solution in the reaction refers to an aqueous solution.
[0081] The compound was purified using silica gel column chromatography and reversed-phase column chromatography. The eluent system was selected from: A: petroleum ether and ethyl acetate system; B: dichloromethane and methanol system; C: dichloromethane: ethyl acetate system; D: trifluoroacetic acid aqueous solution and acetonitrile system. The volume ratio of the solvent varied depending on the polarity of the compound, and small amounts of acidic or basic reagents, such as acetic acid or triethylamine, could be added for adjustment. Example 1 3,4-dichloro-2-(2-(2-hydroxypropan-2-yl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-6-yl)phenol 3,4-dichloro-2-(2-(2-hydroxypropan-2-yl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-6-yl)phenol Step 1 2,3-dichloro-6-methoxybenzaldehyde 2,3-dichloro-6-methoxybenzaldehyde
[0082] 1,2-Dichloro-4-methoxybenzene 1a (50 g, 282.44 mmol) was dissolved in tetrahydrofuran (700 mL), cooled to -78 °C, and n-butyllithium (2.5 M, 124.27 mL) was added under a nitrogen atmosphere. The reaction mixture was stirred at -78 °C for 1 hour, and N,N-dimethylformamide (22.71 g, 310.69 mmol) was added, with stirring continuing for another hour. The mixture was quenched with saturated ammonium chloride solution, extracted with ethyl acetate, concentrated, and the residue was purified by column chromatography (eluent: system A) to give 2,3-dichloro-6-methoxybenzaldehyde 1b (33.2 g), with a yield of 57.33%. MS m / z (ESI): 205.0 [M+1] Step 2: ethyl (E)-3-(2,3-dichloro-6-methoxyphenyl)acrylate (E)-3-(2,3-dichloro-6-methoxyphenyl)acrylate
[0083] 2,3-Dichloro-6-methoxybenzaldehyde 1b (15 g, 73.16 mmol), ethyl 2-diethoxyphosphate (24.60 g, 109.74 mmol), and lithium hydroxide monohydrate (4.60 g, 109.74 mmol) were dissolved in tetrahydrofuran (200 mL), and the reaction mixture was stirred overnight at room temperature. The mixture was quenched with water, extracted with ethyl acetate (200 mL × 3), and the organic phases were combined, washed with saturated brine (100 mL × 3), dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the residue was purified by column chromatography (eluent: system A) to give (E)-3-(2,3-dichloro-6-methoxyphenyl)acrylate 1c (9.6 g), in a yield of 47.70%. MS m / z (ESI): 275.0 [M+1] Step 3: ethyl 3-(2,3-dichloro-6-methoxyphenyl)-4-nitrobutanoate
[0084] Ethyl (E)-3-(2,3-dichloro-6-methoxyphenyl)acrylate 1c (9.6 g, 34.89 mmol) was dissolved in dimethyl sulfoxide (10 mL), and then nitromethane (10.65 g, 174.46 mmol) and cesium carbonate (9.10 g, 27.91 mmol) were added. The reaction mixture was stirred at 70 °C for 18 hours. The mixture was quenched with water, extracted with ethyl acetate, and the organic phase was dried and concentrated to give ethyl 3-(2,3-dichloro-6-methoxyphenyl)-4-nitrobutyrate 1d (9.6 g), in 81.84% yield. MS m / z (ESI): 336.2 [M+1] Step 4: Ethyl 4-amino-3-(2,3-dichloro-6-methoxyphenyl)butanoate
[0085] Ethyl 3-(2,3-dichloro-6-methoxyphenyl)-4-nitrobutyrate 1d (9.6 g, 28.56 mmol) and zinc powder (18.67 g, 285.57 mmol) were dissolved in acetic acid (50 mL), and the reaction solution was reacted at 50 °C for 2 hours. After the reaction was complete, the mixture was filtered, the pH was adjusted to 8 with saturated sodium bicarbonate aqueous solution, extracted with ethyl acetate, and the organic phase was dried and concentrated to give ethyl 4-amino-3-(2,3-dichloro-6-methoxyphenyl)butyrate 1e (8 g), with a yield of 91.49%. MS m / z (ESI): 306.0 [M+1] Step 5 4-(2,3-dichloro-6-methoxyphenyl)pyrrolidin-2-one 4-(2,3-dichloro-6-methoxyphenyl)pyrrolidine-2-one
[0086] Ethyl 4-amino-3-(2,3-dichloro-6-methoxyphenyl)butyrate 1e (8 g, 26.13 mmol) and cesium carbonate (25.54 g, 78.38 mmol) were dissolved in methanol (100 mL). The reaction solution was stirred at 50 °C for 18 hours, filtered, concentrated, and the residue was purified by column chromatography (eluent: system B) to give 4-(2,3-dichloro-6-methoxyphenyl)pyrrolidine-2-one 1f (6.2 g), with a yield of 91.23%. MS m / z (ESI): 260.0 [M+1] Step 6: methyl 2-(4-(2,3-dichloro-6-methoxyphenyl)-2-oxopyrrolidin-1-yl)acetate
[0087] 1f of 4-(2,3-dichloro-6-methoxyphenyl)pyrrolidone-2-one (600 mg, 2.31 mmol) and potassium tert-butoxide (516.69 mg, 4.61 mmol) were dissolved in N,N-dimethylformamide (4 mL). The mixture was stirred at room temperature for 20 minutes under nitrogen protection, and then cooled to 0 °C. A solution of methyl bromoacetate (519 mg, 3.41 mmol) in N,N-dimethylformamide (2 mL) was added dropwise to the reaction solution. After the addition was complete, the mixture was stirred at room temperature for 2 hours. The reaction was quenched with water, extracted with ethyl acetate (15 mL × 3), the organic phases were combined, washed with brine (30 mL), dried over anhydrous sodium sulfate, concentrated under reduced pressure, and the residue was purified by reversed-phase column chromatography (eluent: system D) to give 1 g (490 mg) of methyl 2-(4-(2,3-dichloro-6-methoxyphenyl)-2-oxopyrrolidin-1-yl)acetamide, yield 64.0%. MS m / z (ESI): 332.0 [M+1] Step 7 2-(4-(2,3-dichloro-6-methoxyphenyl)-2-oxopyrrolidin-1-yl)acetamide
[0088] Under nitrogen protection, a methanol solution of ammonia (4 mL, 4 M) was added to a methanol solution of 1 g (490 mg, 1.48 mmol) of methyl 2-(4-(2,3-dichloro-6-methoxyphenyl)-2-oxopyrrolidone-1-yl)acetate at 0 °C. The mixture was then stirred at 40 °C under nitrogen protection for 16 hours. The reaction solution was concentrated under reduced pressure, and the residue was purified by reversed-phase column chromatography (eluent: system D) to give 2-(4-(2,3-dichloro-6-methoxyphenyl)-2-oxopyrrolidone-1-yl)acetamide 1 h (360 mg), yield 77.0%. MS m / z (ESI): 316.7 [M+1] Step 8 2-bromo-6-(2,3-dichloro-6-methoxyphenyl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazole
[0089] 2-(4-(2,3-dichloro-6-methoxyphenyl)-2-oxopyrrolidine-1-yl)acetamide 1h (360 mg, 1.14 mmol) and phosphorus tribromooxy (967.06 mg, 3.41 mmol) were dissolved in acetonitrile (2 mL), and the mixture was heated to 85 °C and stirred for 3 hours under nitrogen protection. The reaction mixture was cooled to room temperature, filtered, and the solid was washed with methanol (5 mL) and dried under reduced pressure to give 2-bromo-6-(2,3-dichloro-6-methoxyphenyl)-6,7-dihydro-5h-pyrrolo[1,2-a]imidazole 1i (300 mg), yield 73.0%. MS m / z (ESI): 361.0 [M+1] Step 9 2-(2-bromo-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-6-yl)-3,4-dichlorophenol
[0090] 2-Bromo-6-(2,3-dichloro-6-methoxyphenyl)-6,7-dihydro-5h-pyrrolo[1,2-a]imidazol 1i (7.83 g, 21.63 mmol) was added to dichloromethane (80 mL), and boron tribromide (27.09 g, 108.13 mmol) was added at 0 °C. The reaction was carried out at 0 °C for 1 hour. The mixture was cooled to -7 °C, quenched with methanol, heated to 0 °C, and the pH was adjusted to 7-8 with saturated sodium bicarbonate solution. The mixture was filtered, and the solid was dried under reduced pressure to give 2-(2-bromo-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-6-yl)-3,4-dichlorophenol 1j (6.23 g), with a yield of 82.8%. MS m / z (ESI): 347.0 [M+1] Step 10 2-bromo-6-(6-((tert-butyldimethylsilyl)oxy)-2,3-dichlorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazole 2-bromo-6-(6-((tert-butyldimethylsilyl)oxy)-2,3-dichlorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazole
[0091] 2-(2-bromo-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-6-yl)-3,4-dichlorophenol 1j (6.23 g, 17.90 mmol) was added to N,N-dimethylformamide (70 mL), followed by imidazole (2.56 g, 37.59 mmol) and tert-butyldimethylchlorosilane (4.05 g, 26.85 mmol). The reaction mixture was allowed to react for 12 hours at room temperature. Water (700 mL) was added to the reaction solution, and the mixture was extracted with ethyl acetate (300 mL × 3). The organic phase was washed with saturated sodium chloride solution (500 mL × 2), dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the residue was separated and purified by silica gel column chromatography (eluent: system A) to give 2-bromo-6-(6-((tert-butyldimethylsilyl)oxy)-2,3-dichlorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazole 1k (8.02 g), with a yield of 96.9%. MS m / z (ESI): 461.2 [M+1] Step 11 methyl 6-(2,3-dichloro-6-hydroxyphenyl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazole-2-carboxylate
[0092] 2-Bromo-6-(6-((tert-butyldimethylsilyl)oxy)-2,3-dichlorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazole 1k (1 g, 2.16 mmol) was added to a mixture of dichloromethane and methanol (30 mL, V / V = 1:1), followed by the addition of triethylamine (459.67 mg, 4.54 mmol) and 1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride (16.56 mg, 432.64 μmol). The reaction was carried out at 80 °C for 16 hours under a carbon monoxide atmosphere (30 psi). The reaction solution was filtered, the filtrate was concentrated under reduced pressure, and the residue was purified by reversed-phase column chromatography (eluent: system D) to give 1 L (532 mg) of methyl 6-(2,3-dichloro-6-hydroxyphenyl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-2-carboxylate, yield 75.2%. MS m / z (ESI): 327.0 [M+1] Step 12 3,4-dichloro-2-(2-(2-hydroxypropan-2-yl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-6-yl)phenol
[0093] 1L (2 g, 6.11 mmol) of methyl 6-(2,3-dichloro-6-hydroxyphenyl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazolium-2-carboxylate was added to tetrahydrofuran (100 mL) under nitrogen protection, and methyl magnesium bromide (3 M, 30.57 mL) was added dropwise at -78 °C. The temperature was raised to 50 °C and the reaction was carried out for 4 hours. The reaction solution was quenched with water (100 mL), extracted with ethyl acetate (100 mL × 3), washed with saturated sodium chloride solution (200 mL × 2), dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the resulting residue was purified by preparative liquid chromatography (Separation column: SunFire Sunfire C18; 19*250 mm, 10 μm, 20 mL / min; Mobile phase A: 0.1% FA / H2O, Mobile phase B: CH3CN) to give 3,4-dichloro-2-(2-(2-hydroxypropyl-2-yl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-6-yl)phenol 1 (513.5 mg), yield 25.7%. MS m / z (ESI): 327.2 [M+1] ¹H NMR (400 MHz, DMSO-d6) δ 10.46 (s, 1H), 8.14 (s, 1H), 7.38 (d, J = 8.0 Hz, 1H), 6.86 (d, J = 8.0 Hz, 1H), 6.84 (s, 1H), 4.81–4.73 (m, 1H), 4.57 (s, 1H), 4.18–4.06 (m, 2H), 3.04–2.98 (m, 2H), 1.38 (d, J = 8.0 Hz, 6H). Examples 2 and 3 (S)-3,4-dichloro-2-(2-(2-hydroxypropan-2-yl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-6-yl)phenol (S)-3,4-dichloro-2-(2-(2-hydroxypropan-2-yl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-6-yl)phenol 2 (R)-3,4-dichloro-2-(2-(2-hydroxypropan-2-yl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-6-yl)phenol (R)-3,4-dichloro-2-(2-(2-hydroxypropan-2-yl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-6-yl)phenol 3
[0094] 3,4-Dichloro-2-(2-(2-hydroxypropyl-2-yl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-6-yl)phenol 1 (260 mg) was purified by chiral preparation (gradient column: DAICELCHIRALPAK® AD, 250*30 mm, 10 µm, flow rate 140 mL / min, gradient: 20% MeOH (+0.1% 7.0 mol / L ammonia methanol): 80% CO2) to obtain compound 2 and compound 3.
[0095] SFC analysis method: DAICELCHIRALPAK® AD, 100*30 mm, 3.0 µm, wavelength: 214 nm, flow rate 1.5 mL / min; gradient: 85% supercritical CO2, 15% MeOH (0.1% DEA); column temperature: 35ºC. Single configuration compound (shorter retention time): MS m / z (ESI): 327.1 [M+1] 104.78 mg, yield 40.3%; retention time 2.393 min, chiral purity 100%ee. 1H NMR (400 MHz, DMSO-d6) δ 10.49 (s, 1H), 8.15 (s, 1H, HCOOH), 7.38 (d, J = 8.0 Hz, 1H), 6.86 (d, J = 8.0 Hz, 1H), 6.83 (s, 1H), 4.84–4.70 (m, 1H), 4.56 (s, 1H), 4.20–4.04 (m, 2H), 3.07–2.92 (m, 2H), 1.38 (d, J = 8.0 Hz, 1H). Hz, 6H). Single configuration compound (longer retention time): MS m / z (ESI): 327.1 [M+1] 93.13 mg, yield 35.82%; retention time 4.126 min, chiral purity 98%ee 1H NMR (400 MHz, DMSO-d6) δ 10.46 (s, 1H), 8.14 (s, 1H, HCOOH), 7.38 (d, J = 8.0 Hz, 1H), 6.86 (d, J = 8.0 Hz, 1H), 6.83 (s, 1H), 4.83–4.71 (m, 1H), 4.57 (s, 1H), 4.18–4.04 (m, 2H), 3.07–2.92 (m, 2H), 1.38 (d, J = 8.0 Hz, 6H). Example 2 Preparation method of compound 2 Step 1 (S)-3-(6-(allyloxy)-2,3-dichlorophenyl)-5-ethoxy-3,4-dihydro-2H-pyrrole (S)-3-(6-(allyloxy)-2,3-dichlorophenyl)-5-ethoxy-3,4-dihydro-2H-pyrrole
[0096] Cesium carbonate (11.96 g, 36.69 mmol) was added to a solution of (S)-4-(6-(allyloxy)-2,3-dichlorophenyl)pyrrolidine-2-one 2a (3.5 g, 12.23 mmol, prepared according to CN117946111) in dichloromethane (50 mL). The reaction was stirred at room temperature for 5 minutes, then triethylonium tetrafluoroborate (2.79 g, 14.68 mmol) was added, and the reaction was carried out at room temperature for 12 hours. Water (50 mL) was added to the reaction solution, and the mixture was extracted with dichloromethane (80 mL × 3). The combined organic phases were washed with saturated sodium chloride solution (50 mL × 2), dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (eluent: system A) to give (S)-3-(6-(allyloxy)-2,3-dichlorophenyl)-5-ethoxy-3,4-dihydro-2H-pyrrolidin-2b (2.4 g), yield 62.5%. MS m / z (ESI): 314.1 [M+1] Step 2: (S)-4-(6-(allyloxy)-2,3-dichlorophenyl)pyrrolidin-2-imine
[0097] (S)-3-(6-(allyloxy)-2,3-dichlorophenyl)-5-ethoxy-3,4-dihydro-2H-pyrrole 2b (2.5 g, 7.96 mmol) was added to methanol (15 mL), followed by ammonium bicarbonate (1.89 g, 23.87 mmol). The reaction was continued at room temperature for 18 hours. After the reaction was completed, the solution was directly concentrated by rotary evaporation, washed with dichloromethane (30 mL), filtered, and the filtrate was evaporated to dryness to give (S)-4-(6-(allyloxy)-2,3-dichlorophenyl)pyrrole-2-imine 2c (1.8 g), with a yield of 79.3%. MS m / z (ESI): 285.1 [M+1] Step 3 (S)-2-(6-(6-(allyloxy)-2,3-dichlorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-2-yl)propan-2-ol (S)-2-(6-(6-(allyloxy)-2,3-dichlorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-2-yl)propan-2-ol
[0098] To a 30 mL ethanol solution of (S)-4-(6-(allyloxy)-2,3-dichlorophenyl)pyrrolidine-2-imine 2c (1.8 g, 6.31 mmol) and sodium bicarbonate (1.59 g, 18.94 mmol) were added. The system was reacted at 80 °C for 12 hours. After the reaction was completed, the product was directly evaporated to dryness. The residue was purified by silica gel column chromatography (eluent: system A) to give (S)-2-(6-(6-(allyloxy)-2,3-dichlorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-2-yl)prop-2-ol 2e (1.5 g), yield 64.7%. MS m / z (ESI): 367.2 [M+1] Step 4 (S)-3,4-dichloro-2-(2-(2-hydroxypropan-2-yl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-6-yl)phenol (S)-3,4-dichloro-2-(2-(2-hydroxypropan-2-yl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-6-yl)phenol
[0099] At room temperature, under nitrogen protection, tetrakis(triphenylphosphine)palladium (378 mg, 326.74 μmol) was added to a solution of (S)-2-(6-(6-(allyloxy)-2,3-dichlorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-2-yl)prop-2-ol 2e (1.2 g, 3.27 mmol) and morpholine (313.12 mg, 3.59 mmol) in N,N-dimethylformamide (15 mL). The mixture was heated to 80 °C and stirred for 3 hours. After the reaction was complete, the mixture was cooled to room temperature, water (30 mL) was added, and the mixture was extracted with ethyl acetate (50 mL × 3). The combined organic phases were washed with saturated sodium chloride solution (30 mL × 2), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was directly purified by silica gel column chromatography (eluent: system D) to give (S)-3,4-dichloro-2-(2-(2-hydroxypropyl-2-yl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-6-yl)phenol 2 (709.65 mg), with a yield of 66.4%. MS m / z (ESI): 327.1 [M+1] 1H NMR (400 MHz, DMSO-d6) δ 10.56 (s, 1H), 7.38 (d, J = 8.8 Hz, 1H), 6.89 – 6.81 (m, 2H), 4.81 – 4.72 (m, 1H), 4.56 (br s, 1H), 4.18 – 4.05 (m, 2H), 3.04 – 2.93 (m, 2H), 1.38 (d, J = 5.6 Hz, 6H). SFC analysis method: Rt = 2.227 min (gradient column: DAICELCHIRALPAK® AD, 100*30 mm, 3.0 µm, wavelength: 214 nm, flow rate 1.5 mL / min; Gradient: 85% supercritical CO2, 15% MeOH (0.1% DEA); Column temperature: 35ºC. Example 3: Preparation method of compound 3, step two: (R)-3-(6-(allyloxy)-2,3-dichlorophenyl)-5-ethoxy-3,4-dihydro-2H-pyrrole (R)-3-(6-(allyloxy)-2,3-dichlorophenyl)-5-ethoxy-3,4-dihydro-2H-pyrrole
[0100] Cesium carbonate (1.02 g, 3.15 mmol) was added to a solution of (R)-4-(6-(allyloxy)-2,3-dichlorophenyl)pyrrolidine-2-one 3a (300 mg, 1.05 mmol, prepared according to CN117946111) in dichloromethane (8 mL), and the reaction was carried out at room temperature for 5 min. Then triethylonium tetrafluoroborate (239.02 mg, 1.26 mmol) was added, and the mixture was stirred for 12 h. Water (30 mL) was added to the reaction mixture, and the mixture was extracted with dichloromethane (50 mL × 3). The combined organic phases were washed with saturated sodium chloride solution (50 mL × 2), dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (eluent: system A) to give (R)-3-(6-(allyloxy)-2,3-dichlorophenyl)-5-ethoxy-3,4-dihydro-2H-pyrrolidin-2-imine (182 mg), yield 55.3%. MS m / z (ESI): 314.1 [M+1] Step 2: (R)-4-(6-(allyloxy)-2,3-dichlorophenyl)pyrrolidin-2-imine
[0101] Ammonium bicarbonate (140.40 mg, 1.78 mmol) was added to methanol (5 mL) containing (R)-3-(6-(allyloxy)-2,3-dichlorophenyl)-5-ethoxy-3,4-dihydro-2H-pyrrole 3b (186.00 mg, 591.97 μmol). The system was reacted at room temperature for 18 hours. After the reaction was completed, the mixture was directly concentrated by rotary evaporation, washed with dichloromethane (30 mL), filtered, and the filtrate was concentrated under reduced pressure to give (R)-4-(6-(allyloxy)-2,3-dichlorophenyl)pyrrole-2-imine 3c (132 mg), with a yield of 78.2%. MS m / z (ESI): 285.1 [M+1] Step 3 (R)-2-(6-(6-(allyloxy)-2,3-dichlorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-2-yl)propan-2-ol (R)-2-(6-(6-(allyloxy)-2,3-dichlorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-2-yl)propan-2-ol
[0102] 1-Bromo-3-hydroxy-3-methylbut-2-one 2d (251.38 mg, 1.39 mmol) and sodium bicarbonate (116.66 mg, 1.39 mmol) were added to (R)-4-(6-(allyloxy)-2,3-dichlorophenyl)pyrrolidine-2-imine 3c (132 mg, 462.88 μmol) in ethanol (3 mL). The system was reacted at 80°C for 12 hours. After the reaction, the mixture was directly evaporated to dryness and purified by thin-layer chromatography (developing solvent: system A) to give (R)-2-(6-(6-(allyloxy)-2,3-dichlorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-2-yl)prop-2-ol 3d (128 mg), yield 75.3%. MS m / z (ESI): 367.2 [M+1] Step 4 (R)-3,4-dichloro-2-(2-(2-hydroxypropan-2-yl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-6-yl)phenol (R)-3,4-dichloro-2-(2-(2-hydroxypropan-2-yl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-6-yl)phenol
[0103] (R)-2-(6-(6-(allyloxy)-2,3-dichlorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-2-yl)prop-2-ol 3d (128.00 mg, 348.52 μmol) was added to tetrahydrofuran (4 mL), followed by sodium borohydride (26.37 mg, 697.04 μmol) and tetratetraphenylphosphine palladium (201.37 mg, 174.26 μmol). The reaction was carried out at room temperature for 2 hours under a nitrogen atmosphere. After the reaction was completed, the mixture was concentrated under reduced pressure. The residue was purified by preparative liquid chromatography (SunFire C18 column; 19*250mm, 10 μm, 20 mL / min; mobile phase A: 0.1% FA / H2O, mobile phase B: CH3CN, gradient: 20%-30%) to obtain (R)-3,4-dichloro-2-(2-(2-hydroxypropyl-2-yl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-6-yl)phenol 3 (21.6 mg), with a yield of 18.9%. MS m / z (ESI): 327.1 [M+1] ¹H NMR (400 MHz, DMSO-d6) δ 10.46 (s, 1H), 7.38 (d, J = 8.0 Hz, 1H), 6.87 (d, J = 8.0 Hz, 1H), 6.82 (s, 1H), 4.84–4.69 (m, 1H), 4.57 (s, 1H), 4.17–4.06 (m, 2H), 3.06–2.92 (m, 2H), 1.38 (d, J = 8.0 Hz, 6H). SFC analysis method: Rt = 4.039 min (gradient column: DAICELCHIRALPAK® AD, 100*30 mm, 3.0 µm, wavelength: 214 nm, flow rate: 1.5 mL / min; gradient: 85% supercritical CO2, 15% MeOH (0.1% DEA); column temperature: 35ºC.Example 4 1-((6-(2,3-dichloro-6-hydroxyphenyl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-2-yl)methyl)-4-methylpiperidin-4-ol 1-((6-(2,3-dichloro-6-hydroxyphenyl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-2-yl)methyl)-4-methylpiperidin-4-ol step 3,4-dichloro-2-(2-(hydroxymethyl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-6-yl)phenol 3,4-dichloro-2-(2-(hydroxymethyl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-6-yl)phenol.
[0104] 1L (1 g, 3.06 mmol) of methyl 6-(2,3-dichloro-6-hydroxyphenyl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazolium-2-carboxylate was added to tetrahydrofuran (20 mL), followed by the addition of lithium aluminum hydride solution (3.36 mL, 3.36 mmol, 1 M) under nitrogen protection at 0°C. The reaction mixture was allowed to react at 0°C for 0.5 hours. After the reaction was complete, water (30 mL) was added at 0°C to quench the reaction. The mixture was extracted with ethyl acetate (30 mL × 3), and the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by reversed-phase column chromatography (eluent: system D) to give 3,4-dichloro-2-(2-(hydroxymethyl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazole-6-yl)phenol 4a (508 mg), yield 55.6%. MS m / z (ESI): 299.1 [M+1] Step 2: 6-(2,3-dichloro-6-hydroxyphenyl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazole-2-carbaldehyde
[0105] 3,4-Dichloro-2-(2-(hydroxymethyl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-6-yl)phenol 4a (508 mg, 1.70 mmol) was added to 1,4-dioxane (10 mL), followed by the addition of manganese dioxide (2.95 g, 33.96 mmol) at 0°C. The reaction mixture was heated to 80°C and reacted for 3 hours. After the reaction was complete, the mixture was filtered, the filter cake was washed with dichloromethane, the filtrate was collected and concentrated under reduced pressure, and the residue was purified by reversed-phase column chromatography (eluent: system D) to obtain 6-(2,3-dichloro-6-hydroxyphenyl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-2-carboxaldehyde 4b (80 mg), with a yield of 15.9%. MS m / z (ESI): 297.1 [M+1] Step 3 1-((6-(2,3-dichloro-6-hydroxyphenyl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-2-yl)methyl)-4-methylpiperidin-4-ol 1-((6-(2,3-dichloro-6-hydroxyphenyl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-2-yl)methyl)-4-methylpiperidin-4-ol
[0106] 6-(2,3-dichloro-6-hydroxyphenyl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazolium-2-carboxaldehyde 4b (25 mg, 84.14 μmol) was added to methanol (2 mL), followed by the addition of 4-methylpiperidin-4-ol (14.54 mg, 126.20 μmol) and sodium cyanoborohydride (26.44 mg, 420.68 μmol). The reaction mixture was reacted at 70°C under nitrogen protection for 1 hour. After the reaction was completed, the reaction solution was directly filtered, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by preparative liquid chromatography (Waters 3767 / Qda column: SunFire C18, 19*250mm, 10um; mobile phase A: 0.1% FA / H2O, B: ACN; flow rate: 20mL / min) to obtain 1-((6-(2,3-dichloro-6-hydroxyphenyl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-2-yl)methyl)-4-methylpiperidin-4-ol 4 (8.8 mg), yield 26.4%. MS m / z (ESI): 396.1 [M+1] ¹H NMR (400 MHz, DMSO-d6) δ 8.25 (s, ¹H), 7.37 (d, J = 8.8 Hz, ¹H), 7.00 (s, ¹H), 6.87 (d, J = 8.8 Hz, ¹H), 4.87 – 4.70 (m, ¹H), 4.22 – 4.16 (m, ¹H), 4.13 – 4.07 (m, ¹H), 3.56 (s, 2H), 3.07 – 2.95 (m, 2H), 2.73 – 2.58 (m, 4H), 1.54 – 1.46 (m, 4H), 1.11 (s, 3H). Example 5 1-((6-(2,3-dichloro-6-hydroxyphenyl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-2-yl)methyl)-3-methylazetidin-3-ol
[0107] 6-(2,3-dichloro-6-hydroxyphenyl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazolium-2-carboxaldehyde 4b (20 mg, 67.31 μmol) was added to methanol (1 mL), followed by the addition of 3-methylazacyclobutane-3-ol (8.80 mg, 100.96 μmol) and sodium cyanoborohydride (21.15 mg, 336.55 μmol). The reaction mixture was reacted at 70 °C under nitrogen protection for 1 hour. After the reaction was completed, the reaction solution was directly filtered, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by preparative liquid chromatography (Waters 2767 / Qda column: SunFire C18, 19*250mm, 10um; mobile phase A: 0.1% FA / H2O, B: ACN; flow rate: 20mL / min) to obtain 1-((6-(2,3-dichloro-6-hydroxyphenyl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-2-yl)methyl)-3-methylazacyclobutane-3-ol 5 (8.88 mg), yield 35.8%. MS m / z (ESI): 368.1 [M+1] ¹H NMR (400 MHz, MeOD-d⁴) δ 7.29 (d, J = 8.8 Hz, 1H), 7.25 (s, 1H), 6.79 (d, J = 8.8 Hz, 1H), 5.04 – 4.95 (m, 1H), 4.30 (d, J = 8.8 Hz, 2H), 4.22 (s, 2H), 4.08 – 4.01 (m, 2H), 3.99 – 3.90 (m, 2H), 3.26 – 3.06 (m, 2H), 1.49 (s, 3H). Example 6 1-((6-(2,3-dichloro-6-hydroxyphenyl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-2-yl)methyl)-3-(trifluoromethyl)azetidin-3-ol
[0108] 6-(2,3-dichloro-6-hydroxyphenyl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazolium-2-carboxaldehyde 4b (20 mg, 67.31 μmol) was added to methanol (1 mL), followed by the addition of 3-(trifluoromethyl)azacyclobutane-3-ol (14.25 mg, 100.96 μmol) and sodium cyanoborohydride (21.15 mg, 336.55 μmol). The reaction mixture was reacted at 70°C under nitrogen protection for 1 hour. After the reaction was completed, the reaction solution was directly filtered, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by preparative liquid chromatography (Waters 2767 / Qda column: SunFire C18, 19*250mm, 10um; mobile phase A: 0.1% FA / H2O, B: ACN; flow rate: 20mL / min) to obtain 1-((6-(2,3-dichloro-6-hydroxyphenyl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-2-yl)methyl)-3-(trifluoromethyl)azacyclobutane-3-ol 6 (10.93 mg), yield 38.5%. MS m / z (ESI): 422.1 [M+1] 1H NMR (400 MHz, MeOD-d4) δ 7.31 (d, J = 8.8 Hz, 1H), 7.30 (s, 1H), 6.80 (d, J = 8.8 Hz, 1H), 5.13 – 5.04 (m, 1H), 4.45 – 4.38 (m, 1H), 4.37 – 4.30 (m, 1H), 4.03 – 3.95 (m, 2H), 3.93 (s, 2H), 3.66 – 3.58 (m, 2H), 3.35 – 3.31 (m, 2H). Examples 7-13 were synthesized according to the synthesis method of Example 4; Examples 14-18 were synthesized according to the synthesis method of Example 1. The specific structures and characterizations of Examples 7-18 are shown in Table 1 below: Table 1 Specific structures and characterizations of Examples 7-18 Example number structure Structural characterization 7 MS m / z (ESI): 368.1 [M+1] 8 MS m / z (ESI): 382.1 [M+1] 9 MS m / z (ESI): 396.3 [M+1] 10 MS m / z (ESI):382.2 [M+1] 11 MS m / z (ESI):354.2 [M+1] 12 MS m / z (ESI):408.3 [M+1] 13 MS m / z (ESI):394.3 [M+1] 14 MS m / z (ESI):361.6 [M+1]; 1 H NMR (400 MHz, DMSO-d6) δ 8.20 (s, 1H), 7.16 (s, 1H), 6.85 (s, 1H), 5.16 – 5.01 (m, 1H), 4.33 – 4.22 (m, 1H), 4.16 – 4.07 (m, 1H), 3.18 – 2.98 (m, 2H), 1.39 (s, 3H), 1.37 (s, 3H). 15 MS m / z (ESI):345.2 [M+1] 16 MS m / z (ESI):328.2 [M+1] 17 MS m / z (ESI):345.2 [M+1] 18 MS m / z (ESI):328.2 [M+1] Example 19 3,4-dichloro-2-(2-(pyrrolidin-3-yl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-6-yl)phenol 3,4-dichloro-2-(2-(pyrrolidin-3-yl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-6-yl)phenol Step 1 3-(2,3-dichloro-6-methoxyphenyl)-5-methoxy-3,4-dihydro-2H-pyrrole 3-(2,3-dichloro-6-methoxyphenyl)-5-methoxy-3,4-dihydro-2H-pyrrole
[0109] 4-(2,3-dichloro-6-methoxyphenyl)pyrrolidin-2-one 1f (5.5 g, 21.14 mmol) was dissolved in dichloromethane (100 mL), and then trimethyloxonium tetrafluoroboric acid (5.99 g, 42.29 mmol) was added. The reaction mixture was stirred at room temperature for 3 hours. After the reaction was completed, the solution was concentrated to obtain 3-(2,3-dichloro-6-methoxyphenyl)-5-methoxy-3,4-dihydro-2H-pyrrolidin 19a (5.8 g), which was directly used in the next step. MS m / z (ESI): 274.0 [M+1] Step 2 4-(2,3-dichloro-6-methoxyphenyl)pyrrolidin-2-imine 4-(2,3-dichloro-6-methoxyphenyl)pyrrolidin-2-imine
[0110] 3-(2,3-dichloro-6-methoxyphenyl)-5-methoxy-3,4-dihydro-2H-pyrrole 19a (4.4 g, 16.05 mmol) was dissolved in methanol (20 mL), and sodium bicarbonate (3.81 g, 48.15 mmol) was added. The reaction mixture was stirred at room temperature for 18 hours. After the reaction was complete, the mixture was filtered and concentrated. The residue was purified by silica gel column chromatography (eluent: system B) to give 4-(2,3-dichloro-6-methoxyphenyl)pyrrolidin-2-imine 19b (1.1 g), in 26.45% yield. MS m / z(ESI): 258.9 [M+1] Step 3: tert-butyl 3-(6-(2,3-dichloro-6-methoxyphenyl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-2-yl)pyrrolidine-1-carboxylate
[0111] At room temperature, sodium bicarbonate (97.48 mg, 1.16 mmol) was added to an ethanol (4 mL) solution of 3-(2-bromoacetyl)pyrrolidine-1-carboxylic acid tert-butyl ester 19c (226 mg, 773.53 μmol, prepared according to published patent "WO2010051245") and 4-(2,3-dichloro-6-methoxyphenyl)pyrrolidine-2-imine 19b (100.22 mg, 386.76 μmol). The reaction mixture was stirred at 80 °C for 16 hours under nitrogen protection. After the reaction was complete, the mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: system B) to give tert-butyl 3-(6-(2,3-dichloro-6-methoxyphenyl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-2-yl)pyrrolo[1,2-a]imidazol-6-yl)phenol 19d (80 mg), yield 45.72%. MS m / z (ESI): 452.1 [M+1] Step 4: 3,4-dichloro-2-(2-(pyrrolidin-3-yl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-6-yl)phenol
[0112] At -78°C, boron tribromide (100 mg, 0.4 mmol) was added to a solution of 19d (70 mg, 154.74 μmol) of 3-(6-(2,3-dichloro-6-methoxyphenyl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-2-yl)pyrrolidine-1-carboxylic acid tert-butyl ester 154.74 carboxylic acid 154.74 mmol) in dichloromethane. The reaction mixture was then stirred at 0°C for 10 minutes. After the reaction was complete, it was quenched with methanol at -78°C, and the pH was adjusted to 8 with saturated sodium bicarbonate solution. The system was filtered and the filter cake was washed with dichloromethane. The filtrates were combined and the solvent was removed under reduced pressure. The residue was purified by preparative liquid chromatography (SunFire C18[UNK]19*250 mm[UNK] 10 μm column; 20 ml / min; mobile phase A: 10 mmol / L, 0.1% formic acid / water; mobile phase B: acetonitrile; flow rate: 20 mL / min) to obtain 3,4-dichloro-2-(2-(pyrrolidine-3-yl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-6-yl)phenol 19 (17.8 mg), yield 34.01%. MS m / z(ESI): 337.8 [M+1] 1H NMR (400 MHz, DMSO-d 6)δ8.30 (s, 1H), 7.37 (dd, J = 8.8, 1.8 Hz, 1H), 7.01 – 6.95 (m, 1H), 6.88 (dd, J = 8.7, 3.7 Hz, 1H), 4.83 – 4.70 (m, 1H), 4.21 – 4.04 (m, 2H), 3.46 – 3.23 (m, 4H), 3.26 – 3.09 (m, 2H), 3.10 – 2.91 (m, 2H), 2.24 – 2.12 (m, 1H), 2.04 – 1.89 (m, 1H) ppm. Example 20 3,4-dichloro-2-(2-ethyl-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-6-yl)phenol 3,4-dichloro-2-(2-ethyl-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-6-yl)phenol Step 1 6-(2,3-dichloro-6-methoxyphenyl)-2-ethyl-6,7-dihydro-5H-pyrrolo[1,2-a]imidazole 6-(2,3-dichloro-6-methoxyphenyl)-2-ethyl-6,7-dihydro-5H-pyrrolo[1,2-a]imidazole
[0113] Sodium bicarbonate (97.26 mg, 1.16 mmol) was added to an ethanol (4 mL) solution of 4-(2,3-dichloro-6-methoxyphenyl)pyrrolidine-2-imine 19b (100 mg, 385.90 μmol) and 1-bromobut-2-one 20a (116.54 mg, 771.81 μmol). The reaction mixture was then stirred at 80 °C under nitrogen protection for 16 hours. After the reaction was complete, the reaction mixture was concentrated under reduced pressure, and the residue was purified by column chromatography (eluent: system B) to give 6-(2,3-dichloro-6-methoxyphenyl)-2-ethyl-6,7-dihydro-5H-pyrrolo[1,2-a]imidazolium 20b (50 mg), in a yield of 41.63%. MS m / z(ESI): 311.0 [M+1] Step 2 3,4-dichloro-2-(2-ethyl-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-6-yl)phenol
[0114] At -78°C, boron tribromide (80 mg, 321.32 μmol) was added to a solution of 6-(2,3-dichloro-6-methoxyphenyl)-2-ethyl-6,7-dihydro-5H-pyrrolo[1,2-a]imidazole 20b (40 mg, 128.53 μmol) in dichloromethane (2 mL). The reaction mixture was then stirred at 0°C for 10 minutes. After the reaction was complete, methanol was added at -78°C to quench the reaction, and the pH was adjusted to 8 with saturated sodium bicarbonate solution. The mixture was filtered, the filter cake was washed with dichloromethane, and the solvent was removed from the filtrate under reduced pressure. The residue was purified by preparative liquid chromatography (Waters 3767 / QDA column: SunFire C18, 19*250 mm, 10 μm; mobile phase A: 10 mmol / L; A: 0.1% formic acid / water; B: acetonitrile; flow rate: 20 mL / min) to obtain 20 (13.1 mg) of 3,4-dichloro-2-(2-ethyl-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-6-yl)phenol, with a yield of 34.30%.MS m / z (ESI): 297.0 [M+1] ¹H NMR (400 MHz, DMSO-d₆) δ 10.55 (s, ¹H), 7.41 (d, J = 8.8 Hz, ¹H), 7.19 (s, ¹H), 6.87 (d, J = 8.8 Hz, ¹H), 4.98 – 4.83 (m, ¹H), 4.39 (t, J = 10.2 Hz, ¹H), 4.15 (dd, J = 10.4, 7.0 Hz, 2H), 3.22 – 3.10 (m, 2H), 2.59 (q, J = 7.5 Hz, 4H), 1.19 (t, J = 7.5 Hz, 3H) ppm. Example 21 2-(2-(1H-pyrazol-4-yl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-6-yl)-3,4-dichlorophenol 2-(2-(1H-pyrazol-4-yl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-6-yl)-3,4-dichlorophenol tert-butyl 4-(6-(2,3-dichloro-6-methoxyphenyl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-2-yl)-1H-pyrazole-1-carboxylate 4-(6-(2,3-dichloro-6-methoxyphenyl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-2-yl)-1H-pyrazole-1-carboxylic acid tert-butyl ester
[0115] 2-(2-bromo-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-6-yl)-3,4-dichlorophenol 1j (100 mg, 276.21 μmol), 1-Boc-pyrazole-4-boronic acid pinacol ester 21a (162.49 mg, 552.41 μmol, commercially available), cesium carbonate (359.97 mg, 1.10 mmol), and [1,1'-bis(diphenylphosphine)ferrocene]palladium dichloride (40.98 mg, 55.24 μmol) were added to 1,4-dioxane (2 mL) and water (0.5 mL), and the mixture was stirred at 100 °C for 18 hours. After the reaction was complete, the mixture was filtered, concentrated, and purified by silica gel column chromatography (eluent: system B) to give 21b (124 mg) of 4-(6-(2,3-dichloro-6-methoxyphenyl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-2-yl)-1H-pyrazole-1-carboxylic acid tert-butyl ester, yield 99.91%. MS m / z (ESI): 349.0 [M-100]. Step 2: 2-(2-(1H-pyrazol-4-yl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-6-yl)-3,4-dichlorophenol
[0116] 4-(6-(2,3-dichloro-6-methoxyphenyl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-2-yl)-1H-pyrazole-1-carboxylic acid tert-butyl ester 21b (124 mg, 275.97 μmol) was dissolved in dichloromethane (1 mL), and boron tribromide (206.98 mg, 827.90 μmol) was added dropwise under ice bath, and the mixture was stirred for 2 hours. After the reaction was complete, water was added to quench the reaction (15 mL), followed by neutralization with saturated sodium bicarbonate solution. The mixture was extracted with ethyl acetate (20 mL × 3), and the combined organic phases were washed with saturated sodium chloride solution (20 mL). The mixture was dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by preparative liquid chromatography (Separation column: SunFire C18 [UNK] 19*250 mm [UNK] 10 μm; 20 mL / min; Mobile phase A: 10 mmol / L, 0.1% formic acid / water; Mobile phase B: acetonitrile; Flow rate: 20 mL / min) to obtain 2-(2-(1H-pyrazol-4-yl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-6-yl)-3,4-dichlorophenol 21 (19.8 mg), with a yield of 20.85%. MS m / z(ESI): 335.0 [M+1]. 1H NMR (400 MHz, DMSO-d6)δ7.74 (s, 2H), 7.16 (s, 1H), 7.10 (d, J = 8.8 Hz, 1H), 6.52 (d, J = 8.8 Hz, 1H), 4.80 – 4.66 (m, 1H), 4.21 (t, J = 8.8 Hz, 1H), 4.09 (t, J = 9.6 Hz, 1H), 3.17 (dd, J = 15.1, 8.2 Hz, 1H), 2.88 (dd, J = 15.2, 9.7 Hz, 1H) ppm. Example 22 3,4-dichloro-2-(2-(2-hydroxypropan-2-yl)-6-methyl-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-6-yl)phenol 3,4-dichloro-2-(2-(2-hydroxypropan-2-yl)-6-methyl-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-6-yl)phenol 2,3-dichloro-6-methoxyphenyl)methanol
[0117] 2,3-Dichloro-6-methoxybenzaldehyde 1b (20 g, 97.54 mmol) was dissolved in tetrahydrofuran (200 mL). Sodium borohydride (7.38 g, 195.09 mmol) was added under nitrogen protection at 0°C, and the mixture was then heated to 25°C and reacted for 16 hours. The reaction solution was diluted with water (400 mL), extracted with ethyl acetate (400 mL × 3), and the combined organic phases were washed with saturated sodium chloride solution (600 mL × 2). The mixture was dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (eluent: system A) to give (2,3-dichloro-6-methoxyphenyl)methanol 22a (20 g), with a yield of 99.0%. MS m / z (ESI): 207.0 [M+1] Step 2: 1,2-dichloro-3-(chloromethyl)-4-methoxybenzene
[0118] (2,3-dichloro-6-methoxyphenyl)methanol 22a (20 g, 96.59 mmol), methanesulfonyl chloride (22.13 g, 193.19 mmol), and triethylamine (24.44 g, 241.48 mmol) were added sequentially to dichloromethane (200 mL). The reaction mixture was reacted at 25°C for 16 hours under nitrogen protection. After the reaction was complete, water (300 mL) was added to quench the reaction mixture, and the mixture was extracted with dichloromethane (300 mL × 3). The combined organic phases were washed with saturated sodium chloride solution (400 mL × 2), dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (eluent: system A) to give 1,2-dichloro-3-(chloromethyl)-4-methoxyphenyl 22b (14 g), with a yield of 64.2%. MS m / z (ESI): 225.0 [M+1] Step 3: 2-(2,3-dichloro-6-methoxyphenyl)acetonitrile 2-(2,3-dichloro-6-methoxyphenyl)acetonitrile
[0119] 1,2-Dichloro-3-(chloromethyl)-4-methoxyphenyl 22b (14 g, 62.08 mmol) was dissolved in dimethyl sulfoxide (140 mL), and sodium cyanide (9.88 g, 186.25 mmol) was added. The reaction mixture was heated to 90°C and reacted for 4 hours. After the reaction was complete, the reaction solution was diluted with saturated sodium bicarbonate solution (400 mL), extracted with ethyl acetate (400 mL × 3), and the combined organic phases were washed with saturated sodium chloride solution (500 mL × 2). The mixture was dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (eluent: system A) to give 2-(2,3-dichloro-6-methoxyphenyl)acetonitrile 22c (12 g), with a yield of 89.4%. MS m / z (ESI): 216.0 [M+1] Step 4: 2-(2,3-dichloro-6-methoxyphenyl)propanenitrile 2-(2,3-dichloro-6-methoxyphenyl)propanenitrile
[0120] 2-(2,3-dichloro-6-methoxyphenyl)acetonitrile 22c (12 g, 55.54 mmol) was dissolved in N,N-dimethylformamide (120 mL), and iodomethane (11.82 g, 83.31 mmol) and cesium carbonate (36.19 g, 111.08 mmol) were added. The reaction mixture was reacted at room temperature under nitrogen protection for 16 hours. After the reaction was complete, the reaction solution was diluted with water (200 mL), extracted with ethyl acetate (200 mL × 3), the organic phase was washed with saturated sodium chloride solution (300 mL × 2), dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the residue was separated and purified by silica gel column chromatography (eluent: system A) to give 2-(2,3-dichloro-6-methoxyphenyl)propionitrile 22d (10.5 g), with a yield of 82.1%. MS m / z (ESI): 230.0 [M+1] Step 5: Ethyl 3-cyano-3-(2,3-dichloro-6-methoxyphenyl)butanoate
[0121] 22d (10.5 g, 45.63 mmol) of 2-(2,3-dichloro-6-methoxyphenyl)propionitrile was dissolved in tetrahydrofuran (110 mL). The reaction mixture was cooled to -70°C under nitrogen protection. Bistrimethylsilylaminolithium (1 M, 68 mL) was slowly added dropwise to the reaction mixture. After the addition was complete, the reaction mixture was stirred at -70°C for 1 hour. Then, ethyl bromoacetate (15.24 g, 91.27 mmol) was added. After the addition was complete, the reaction mixture was slowly heated to 25°C and stirred for 16 hours. After the reaction was complete, water (200 mL) was added to the reaction solution for dilution, and the mixture was extracted with ethyl acetate (200 mL × 3). The organic phase was washed with saturated sodium chloride solution (400 mL × 2), dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (eluent: system A) to give ethyl 3-cyano-3-(2,3-dichloro-6-methoxyphenyl)butyrate 22e (10 g), yield 69.3%. MS m / z (ESI): 316.0 [M+1] Step 6 4-(2,3-dichloro-6-methoxyphenyl)-4-methylpyrrolidin-2-one 4-(2,3-dichloro-6-methoxyphenyl)-4-methylpyrrolidin-2-one
[0122] Ethyl 3-cyano-3-(2,3-dichloro-6-methoxyphenyl)butyrate 22e (5 g, 15.81 mmol) was dissolved in methanol (50 mL), and Raney nickel (928 mg, 15.81 mmol) was added. The reaction mixture was stirred at 25°C for 2 hours under a hydrogen atmosphere (30 psi). After the reaction was complete, the reaction solution was filtered, the residue was washed with methanol, and the resulting filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: system A) to give 4-(2,3-dichloro-6-methoxyphenyl)-4-methylpyrrolidone-2-one 22f (2 g), with a yield of 46.1%. MS m / z (ESI): 274.0 [M+1] Step 7: methyl 2-(4-(2,3-dichloro-6-methoxyphenyl)-4-methyl-2-oxopyrrolidin-1-yl)acetate
[0123] 22f of 4-(2,3-dichloro-6-methoxyphenyl)-4-methylpyrrolidone-2-one (2 g, 7.30 mmol) was dissolved in N,N-dimethylformamide (20 mL), and then potassium tert-butoxide (1.64 g, 14.59 mmol) and methyl bromoacetate (1.67 g, 10.94 mmol) were added, respectively. The reaction mixture was stirred at 60°C for 16 hours under nitrogen protection. After the reaction was complete, water was added to dilute the reaction solution (50 mL), and the mixture was extracted with ethyl acetate (50 mL × 3). The organic phase was washed with saturated sodium chloride solution (80 mL × 2), dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (eluent: system A) to give 22 g (1.5 g) of methyl 2-(4-(2,3-dichloro-6-methoxyphenyl)-4-methyl-2-oxopyrrolidin-1-yl)acetamide, yield 59.3%. MS m / z (ESI): 346.0 [M+1] Step 8 2-(4-(2,3-dichloro-6-methoxyphenyl)-4-methyl-2-oxopyrrolidin-1-yl)acetamide
[0124] 22 g (2 g, 5.78 mmol) of methyl 2-(4-(2,3-dichloro-6-methoxyphenyl)-4-methyl-2-oxopyrrolidine-1-yl)acetate was dissolved in methanol (5 mL), and a methanol solution of ammonia (4 M, 15 mL) was added. The reaction mixture was reacted at 40°C for 16 h. After the reaction was complete, the reaction mixture was concentrated under reduced pressure to give 22 h (1.5 g) of 2-(4-(2,3-dichloro-6-methoxyphenyl)-4-methyl-2-oxopyrrolidine-1-yl)acetamide in 78.4% yield, which was used directly in the next step without further purification. MS m / z (ESI): 331.0 [M+1] Step 9 2-bromo-6-(2,3-dichloro-6-methoxyphenyl)-6-methyl-6,7-dihydro-5H-pyrrolo[1,2-a]imidazole 2-bromo-6-(2,3-dichloro-6-methoxyphenyl)-6-methyl-6,7-dihydro-5H-pyrrolo[1,2-a]imidazole
[0125] 2-(4-(2,3-dichloro-6-methoxyphenyl)-4-methyl-2-oxopyrrolidone-1-yl)acetamide 22h (1.50 g, 4.53 mmol) was dissolved in acetonitrile (15 mL), and phosphorus tribromooxyphosphine (3.90 g, 13.59 mmol) was added. The reaction mixture was reacted at 85°C for 3 hours. After the reaction was complete, water (50 mL) was added to dilute the reaction solution, and the mixture was extracted with ethyl acetate (50 mL × 3). The organic phase was washed with saturated sodium chloride solution (60 mL × 2), dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the residue was separated and purified by silica gel column chromatography (eluent: system A) to give 2-bromo-6-(2,3-dichloro-6-methoxyphenyl)-6-methyl-6,7-dihydro-5H-pyrrolo[1,2-a]imidazole 22i (1.4 g), with a yield of 82.1%. MS m / z (ESI): 375.0 [M+1] Step 10 2-(2-bromo-6-methyl-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-6-yl)-3,4-dichlorophenol
[0126] Under nitrogen protection, 2-bromo-6-(2,3-dichloro-6-methoxyphenyl)-6-methyl-6,7-dihydro-5H-pyrrolo[1,2-a]imidazolium 22i (1.4 g, 3.72 mmol) was dissolved in dichloromethane (14 mL), the reaction system was cooled to -78°C, and then boron tribromide (4 mL) was added dropwise at -78°C. After the addition was completed, the reaction mixture was heated to 0°C and reacted for 30 minutes. After the reaction was completed, the reaction mixture was cooled to -78°C, and then quenched with methanol (30 mL). Ammonia was added to adjust the pH to 8-9. The reaction mixture was concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography (eluent: system B) to give 2-(2-bromo-6-methyl-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-6-yl)-3,4-dichlorophenol 22j (600 mg), with a yield of 44.5%. MS m / z (ESI): 360.8 [M+1] Step 11 2-bromo-6-(6-((tert-butyldimethylsilyl)oxy)-2,3-dichlorophenyl)-6-methyl-6,7-dihydro-5H-pyrrolo[1,2-a]imidazole 2-bromo-6-(6-((tert-butyldimethylsilyl)oxy)-2,3-dichlorophenyl)-6-methyl-6,7-dihydro-5H-pyrrolo[1,2-a]imidazole
[0127] 2-(2-bromo-6-methyl-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-6-yl)-3,4-dichlorophenol 22j (600 mg, 1.66 mmol) was dissolved in N,N-dimethylformamide (5 mL), and imidazole (225 mg, 3.31 mmol) and tert-butyldimethylchlorosilane (299 mg, 1.99 mmol) were added respectively. The reaction mixture was then reacted at 25°C for 16 hours under nitrogen protection. After the reaction was complete, water was added to dilute the reaction solution (30 mL), and the mixture was extracted with ethyl acetate (30 mL × 3). The organic phase was washed with saturated sodium chloride solution (50 mL × 2), dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the residue was separated and purified by silica gel column chromatography (eluent: system A) to give 2-bromo-6-(6-((tert-butyldimethylsilyl)oxy)-2,3-dichlorophenyl)-6-methyl-6,7-dihydro-5H-pyrrolo[1,2-a]imidazole 22k (300 mg), with a yield of 38.0%. MS m / z (ESI): 475.0 [M+1] Step 12 methyl 6-(2,3-dichloro-6-hydroxyphenyl)-6-methyl-6,7-dihydro-5H-pyrrolo[1,2-a]imidazole-2-carboxylate methyl 6-(2,3-dichloro-6-hydroxyphenyl)-6-methyl-6,7-dihydro-5H-pyrrolo[1,2-a]imidazole-2-carboxylate
[0128] 2-Bromo-6-(6-((tert-butyldimethylsilyl)oxy)-2,3-dichlorophenyl)-6-methyl-6,7-dihydro-5H-pyrrolo[1,2-a]imidazolium 22k (300 mg, 0.62 mmol), tritert-butylphosphine tetrafluoroborate (36 mg, 0.12 mmol), molybdenum hexacarbonyl (166 mg, 0.62 mmol), triethylamine (127 mg, 1.26 mmol) and 1,1'-bis(diphenylphosphino)ferrocene palladium dichloride (II) (51 mg, 0.06 mmol) were added sequentially to a mixed solvent of N,N-dimethylformamide (2 mL) and methanol (2 mL). The reaction mixture was reacted at 90°C for 1 hour under nitrogen protection. After the reaction was complete, water was added to dilute the reaction solution (10 mL), and the mixture was extracted with ethyl acetate (10 mL × 3). The organic phase was washed with saturated sodium chloride solution (15 mL × 2), dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the residue was separated and purified by silica gel column chromatography (eluent: system B) to give 22 l (80 mg) of methyl 6-(2,3-dichloro-6-hydroxyphenyl)-6-methyl-6,7-dihydro-5H-pyrrolo[1,2-a]imidazolium-2-carboxylate, with a yield of 37.2%. MS m / z (ESI): 340.9 [M+1] Step Thirteen 3,4-dichloro-2-(2-(2-hydroxypropan-2-yl)-6-methyl-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-6-yl)phenol
[0129] Under nitrogen protection, 22L (60 mg, 0.17 mmol) of methyl 6-(2,3-dichloro-6-hydroxyphenyl)-6-methyl-6,7-dihydro-5H-pyrrolo[1,2-a]imidazolium-2-carboxylate was dissolved in tetrahydrofuran (2 mL). The reaction system was cooled to 0°C, and then methyl magnesium bromide (3 M, 586 μL) solution was added. After the addition was completed, the reaction mixture was heated to 50°C and stirred for 3 hours. After the reaction was complete, water was added to dilute the reaction solution (10 mL), and the mixture was extracted with ethyl acetate (10 mL × 3). The organic phase was washed with saturated sodium chloride solution (20 mL × 2), dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the residue was purified by preparative liquid chromatography (Separation column: SunFire Sunfire C18; 250 × 19 mm ID; 10 µm, 20 mL / min; Mobile phase A: 0.1% FA / H2O, Mobile phase B: CH3CN) to give 22 (7 mg) of 3,4-dichloro-2-(2-(2-hydroxypropyl-2-yl)-6-methyl-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-6-yl)phenol, with a yield of 11.6%. MS m / z(ESI): 340.9 [M+1] 1H NMR (400 MHz, DMSO-d 6) δ 10.70 (brs, 1H), 8.38 (brs, 1H), 7.35 (d, J = 8.8 Hz, 1H), 6.89 (d, J = 8.8 Hz, 1H), 6.87 (s, 1H), 4.51 (d, J = 11.4 Hz, 1H), 4.26 (d, J = 11.5 Hz, 1H), 3.44 (d, J = 15.9 Hz, 1H), 3.21 (d, J = 16.0 Hz, 1H), 1.39 (s, 3H), 1.38 (s, 3H), 1.37 (s, 3H).
[0130] Examples 23-25, 27, and 28-31 were synthesized according to the synthesis method of Example 21; Example 26 was synthesized according to the synthesis method of Example 20; and Example 32 was synthesized according to the synthesis method of Example 22. The specific structures and characterizations of Examples 23-32 are shown in Table 2 below: Table 2 Specific structures and characterizations of Examples 23-32 Example number structure MS m / z (ESI) 1 H NMR twenty three 295.0 [M+1] 1 H NMR (400 MHz, DMSO-d6) δ 8.26 (s, 1H), 7.38 (d, J = 8.8 Hz, 1H), 7.15 (s, 1H), 6.86 (d, J = 8.8 Hz, 1H), 6.52 (dd, J = 17.4, 11.0 Hz, 1H), 5.64 (dd, J = 17.4, 2.2 Hz, 1H), 5.00 (dd, J = 10.9, 2.2 Hz, 1H), 4.88 – 4.75 (m, 1H), 4.28 – 4.19 (m, 1H), 4.13 – 4.04 (m, 1H), 3.09 – 3.02 (m, 2H). 24 363.0 [M+1] 1 H NMR (400 MHz, DMSO-d6) δ 10.64 (s, 1H), 8.11 (s, 1H), 7.85 – 7.78 (m, 2H), 7.46 – 7.37 (m, 3H), 6.89 (d, J = 8.8 Hz, 1H), 5.09 – 4.98 (m, 1H), 4.66 – 4.56 (m, 1H), 4.36 – 4.26 (m, 1H), 3.69 – 3.57 (m, 1H), 3.38 – 3.28 (m, 1H). 25 346.1 [M+1] 1 H NMR (400 MHz, Methanol-d4) δ 8.88 – 8.50 (m, 2H), 8.30 – 8.12 (m, 3H), 7.31 (d, J = 8.8 Hz, 1H), 6.80 (d, J = 8.8 Hz, 1H), 5.16 – 5.04 (m, 1H), 4.50 – 4.36 (m, 2H), 3.33 (s, 2H). 26 336.8 [M+1] 1H NMR (400 MHz, Methanol-d4) δ 8.48 (s, 1H), 7.52 (s, 1H), 7.31 (d, J = 8.8 Hz, 1H), 6.80 (d, J = 8.8 Hz, 1H), 5.10 – 4.99 (m, 1H), 4.39 – 4.28 (m, 2H), 3.25 – 3.16 (m, 2H). 27 369.1 [M+1] 1 H NMR (400 MHz, DMSO-d6) δ 11.19 (s, 1H), 8.21 – 7.83 (m, 2H), 7.71 (s, 1H), 7.21 (s, 1H), 5.37 – 5.25 (m, 1H), 4.66 – 4.56 (m, 1H), 4.41 – 4.30 (m, 1H), 3.69 – 3.56 (m, 1H), 3.31 – 3.16 (m, 1H). 28 309.0 [M+1] NA 29 335.1 [M+1] NA 30 364.1 [M+1] 1 H NMR (400 MHz, Methanol-d4) δ 7.52 (s, 1H), 7.35 (d, J = 8.8 Hz, 1H), 6.85 (d, J = 8.8 Hz, 1H), 6.31 (s, 1H), 5.25 – 5.12 (m, 1H), 4.64 – 4.53 (m, 1H), 4.48 – 4.35 (m, 1H), 3.61 – 3.48 (m, 1H), 3.47 – 3.36 (m, 1H), 3.32 – 3.26 (m, 4H), 2.91 – 2.78 (m, 2H), 2.76 – 2.64 (m, 2H). 31 327.0 [M+1] 1 H NMR (400 MHz, DMSO-d6) δ 10.84 (s, 1H), 7.72 (s, 1H), 7.20 (d, J = 8.4 Hz, 1H), 5.61 (s, 1H), 5.21 (s, 1H), 5.00 – 4.87 (m, 1H), 4.69 – 4.55 (m, 1H), 4.35 – 4.21 (m, 1H), 3.75 – 3.61 (m, 1H), 3.37 – 3.22 (m, 1H), 2.03 (s, 3H). 32 359.1 [M+1] 1 H NMR (400 MHz, DMSO-d6) δ 6.97 – 6.85 (m, 2H), 4.57 – 4.49 (m, 1H), 4.45 – 4.37 (m, 1H), 4.31 – 4.24 (m, 1H), 3.28 – 3.20 (m, 1H), 1.41 (s, 3H), 1.38 (s, 3H), 1.37 (s, 3H). Synthesis of Comparative Compound A: (R)-3,4-dichloro-2-(3-(hydroxymethyl)-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazol-6-yl)phenol; (R)3,4-dichloro-2-(3-(hydroxymethyl)-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazol-6-yl)phenol; Step 1: (R)-3-(6-(allyloxy)-2,3-dichlorophenyl)-5-ethoxy-3,4-dihydro-2H-pyrrole; (R)-3-(6-(allyloxy)-2,3-dichlorophenyl)-5-ethoxy-3,4-dihydro-2H-pyrrole.
[0131] (R)-4-(6-(allyloxy)-2,3-dichlorophenyl)pyrrolidone-2-one A-01 (1 g, 3.49 mmol, prepared according to CN117946111) was added to dichloromethane (20 mL), followed by the addition of cesium carbonate (3.42 g, 10.48 mmol) and triethyloxonium tetrafluoroborate (995.86 mg, 5.24 mmol). The reaction mixture was reacted at room temperature for 12 hours under nitrogen protection. After the reaction was complete, water (100 mL) was added to the reaction solution, and the mixture was extracted with dichloromethane (50 mL × 3). The organic phase was washed with saturated sodium chloride solution (80 mL × 2), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: system A) to give (R)-3-(6-(allyloxy)-2,3-dichlorophenyl)-5-ethoxy-3,4-dihydro-2H-pyrrolo[2,1-c][1,2,4]triazol-3-yl)methanol. The yield was 81.53%. MS m / z (ESI): 313.9 [M+1]. Step 2: (R)-(6-(6-(allyloxy)-2,3-dichlorophenyl)-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazol-3-yl)methanol.
[0132] (R)-3-(6-(allyloxy)-2,3-dichlorophenyl)-5-ethoxy-3,4-dihydro-2H-pyrrole A-02 (500 mg, 1.59 mmol) was added to n-butanol (20 mL), followed by the addition of 2-hydroxyacetylhydrazine (430.04 mg, 4.77 mmol). The reaction mixture was reacted at 140 °C for 12 hours under nitrogen protection. After the reaction was complete, the mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: system B) to give (R)-(6-(6-(allyloxy)-2,3-dichlorophenyl)-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazol-3-yl)methanol A-03 (360 mg), in 66.50% yield. MS m / z (ESI): 340.1 [M+1] Step 3 (R)-3,4-dichloro-2-(3-(hydroxymethyl)-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazol-6-yl)phenol (R)-3,4-dichloro-2-(3-(hydroxymethyl)-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazol-6-yl)phenol
[0133] (R)-(6-(6-(allyloxy)-2,3-dichlorophenyl)-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazol-3-yl)methanol A-03 (180 mg, 529.09 μmol) was added to tetrahydrofuran (10 mL), followed by the addition of sodium borohydride (40.21 mg, 1.06 mmol) and tetra(triphenylphosphine)palladium (61.14 mg, 52.91 μmol). The reaction mixture was reacted at room temperature for 4 hours under nitrogen protection. After the reaction was complete, water (10 mL) was added to the reaction solution, and the mixture was extracted with ethyl acetate (20 mL × 3). The organic phase was washed with saturated sodium chloride solution (30 mL × 2), dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the residue was purified by preparative liquid chromatography (Waters 3767 / QDA column: SunFire Sunfire C18, 19*250 mm, 10 μm mobile phase A: 0.1% FA / H2O, B: CH3CN; flow rate: 20 mL / min; gradient: 23-33%; retention time: 9.1-11 min, 16 min) to obtain (R)-3,4-dichloro-2-(3-(hydroxymethyl)-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazol-6-yl)phenol A (48.88 mg), with a yield of 30.78%. MS m / z (ESI): 300.0 [M+1] 1H NMR (400 MHz, DMSO-d6) δ 10.58 (s, 1H), 7.40 (d, J = 8.8 Hz, 1H), 6.86 (d, J = 8.8 Hz, 1H), 5.49 (t, J = 5.8 Hz, 1H), 5.02 – 4.91 (m, 1H), 4.54 (d, J = 5.3 Hz, 2H), 4.26 (t, J = 10.0 Hz, 1H), 4.16 – 4.07 (m, 1H), 3.15 – 3.07 (dd, J = 9.0, 4.6 Hz, 2H). SFC analysis method: Rt = 1.505 min (Gradient column: DAICELCHIRALPAK® AD, 100*30 mm, 3.0 µm, wavelength: 214 nm, flow rate 1.5 mL / min; gradient: 85% supercritical CO2, 15% MeOH (0.1% DEA); column temperature: 35ºC.)Synthesis of control compound B: (S)-3,4-dichloro-2-(3-(hydroxymethyl)-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazol-6-yl)phenol; (S)3,4-dichloro-2-(3-(hydroxymethyl)-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazol-6-yl)phenol; Step 1: 3-(6-(allyloxy)-2,3-dichlorophenyl)-5-ethoxy-3,4-dihydro-2H-pyrrole; 3-(6-(allyloxy)-2,3-dichlorophenyl)-5-ethoxy-3,4-dihydro-2H-pyrrole.
[0134] 4-(6-(allyloxy)-2,3-dichlorophenyl)pyrrolidone-2-one AB-1 (500 mg, 1.75 mmol, prepared according to CN117946111) was added to dichloromethane (15 mL), followed by the addition of cesium carbonate (1.71 g, 5.24 mmol) and triethyloxonium tetrafluoroborate (398.36 mg, 2.1 mmol). The reaction mixture was allowed to react at room temperature for 12 hours. After the reaction was complete, water (100 mL) was added to the reaction mixture, and the mixture was extracted with dichloromethane (50 mL × 3). The organic phase was washed with saturated sodium chloride solution (50 mL × 2), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: system A) to give 3-(6-(allyloxy)-2,3-dichlorophenyl)-5-ethoxy-3,4-dihydro-2H-pyrrolo[2,1-c][1,2,4]triazol-3-yl)methanol. MS m / z (ESI): 314.2 [M+1] Step 2: (6-(6-(allyloxy)-2,3-dichlorophenyl)-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazol-3-yl)methanol
[0135] 3-(6-(allyloxy)-2,3-dichlorophenyl)-5-ethoxy-3,4-dihydro-2H-pyrrole AB-2 (408 mg, 1.38 mmol) was added to n-butanol (10 mL), followed by the addition of 2-hydroxyacetylhydrazine (350.91 mg, 3.90 mmol). The reaction mixture was reacted at 140 °C for 12 hours. After the reaction was complete, the mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: system B) to give (6-(6-(allyloxy)-2,3-dichlorophenyl)-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazol-3-yl)methanol AB-3 (385 mg), in 87.15% yield. MS m / z (ESI): 340.1 [M+1] Step 3 (S)-3,4-dichloro-2-(3-(hydroxymethyl)-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazol-6-yl)phenol (S)-3,4-dichloro-2-(3-(hydroxymethyl)-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazol-6-yl)phenol
[0136] (6-(6-(allyloxy)-2,3-dichlorophenyl)-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazol-3-yl)methanol AB-3 (355 mg, 1.04 mmol) was added to tetrahydrofuran (10 mL), followed by the addition of sodium borohydride (78.96 mg, 2.09 mmol) and tetra(triphenylphosphine)palladium (120.58 mg, 104.35 μmol). The reaction mixture was reacted at room temperature for 4 hours under nitrogen protection. After the reaction was complete, water (20 mL) was added to the reaction solution, and the mixture was extracted with ethyl acetate (20 mL × 3). The organic phase was washed with saturated sodium chloride solution (20 mL × 2), dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the residue was purified by preparative liquid chromatography (Waters 3767 / QDA column: XBridge C18, 19*250 mm, 10 μm; mobile phase A: 0.1% FA / H2O, B: ACN; flow rate: 20 mL / min; gradient: 26-36%; retention time: 7.1-8.7 min, 17 min) to obtain a racemic mixture (98 mg). This mixture was then resolved by chiral preparative chromatography (instrument: Waters SFC 150, gradient column: DAICELCHIRALPAK® AD, 250*30 mm, 10 μm, flow rate: 50 mL / min, gradient: 70% supercritical CO2: 30% MeOH (+0.1% 7.0 mol / L) Two compounds were obtained by ammonia-methanol separation (column temperature: room temperature), and then the two compounds were purified by preparative liquid chromatography (separation column: SunFire C18; 19*250mm, 10 μm, 20 mL / min; mobile phase A: 0.1% FA / H2O, mobile phase B: CH3CN) to give (R)-3,4-dichloro-2-(3-(hydroxymethyl)-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazol-6-yl)phenol A (38.56 mg, yield 39.11%) and (S)-3,4-dichloro-2-(3-(hydroxymethyl)-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazol-6-yl)phenol B (35.72 mg, yield 36.20%).Reference compound A MS m / z (ESI): 300.0 [M+1] 1H NMR (400 MHz, DMSO-d6) δ 10.66 (s, 1H), 7.39 (d, J = 8.8 Hz, 1H), 6.86 (d, J = 8.8 Hz, 1H), 5.49 (brs, 1H), 5.03 – 4.90 (m, 1H), 4.54 (d, J = 3.4 Hz, 2H), 4.26 (t, J = 10.0 Hz, 1H), 4.11 (dd, J = 10.5, 7.9 Hz, 1H), 3.11 (dd, J = 9.0, 3.4 Hz, 2H). SFC analysis method: RT=1.531 min (gradient column: DAICELCHIRALPAK® AD, 100*30 mm, 3.0 μm, wavelength: 214 nm, flow rate 1.5 mL / min; gradient: 85% supercritical CO2, 15% MeOH (0.1% DEA); column temperature: 35ºC. Control compound B MS m / z (ESI): 300.0 [M+1] 1H NMR (400 MHz, DMSO-d6) δ 10.60 (s, 1H), 7.40 (d, J = 8.8 Hz, 1H), 6.86 (d, J = 8.8 Hz, 1H), 5.49 (t, J = 5.8 Hz, 1H), 5.02 – 4.90 (m, 1H), 4.54 (d, J = 5.5 Hz, 2H), 4.26 (t, J = 10.0 Hz, 1H), 4.11 (dd, J = 10.5, 7.9 Hz, 1H), 3.11 (dd, J = 9.0, 4.4 Hz, 2H). SFC analytical method: RT = 2.482 min (gradient column: DAICELCHIRALPAK® AD, 100*30 mm, 3.0 µm, wavelength: 214 nm, flow rate 1.5 mL / min; gradient: 85% supercritical CO2, 15% MeOH (0.1% DEA); column temperature: 35ºC. The absolute configurations of control compounds A and B were confirmed by combining the above two control synthesis methods.The control compound C, 3,4-dichloro-2-(3-(2-hydroxy-2-methylpropyl)-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazol-6-yl)phenol, was prepared according to the synthetic method of Example 3 of WO2024088343A1. Biological evaluation test example 1: Manual patch-clamp method for detecting the effect of the compounds of this invention on hKv1.3 potassium ion channels. 1.1 Cells.
[0137] The HEK293 cell line stably expressing the hKv1.3 ion channel used in this experiment was constructed by Kanglong Chemical. This cell line was cultured in a medium containing 90% DMEM (Thermo Fisher Scientific), 10% fetal bovine serum, 100 U / mL penicillin-streptomycin solution (Thermo Fisher Scientific), and 6 μg / mL puromycin (Sigma-Aldrich). Before the experiment, the cells were digested and seeded at a density of 5 × 10⁵ cells in 3.5 cm culture dishes containing coverslips for subsequent manual patch-clamp experiments. 1.2 Experimental Solutions
[0138] 1) Extracellular fluid: 132 mM sodium chloride, 4 mM potassium chloride, 3 mM calcium chloride, 0.5 mM magnesium chloride, 11.1 mM glucose and 10 mM HEPES (pH adjusted to 7.35 using sodium hydroxide).
[0139] 2) Intracellular fluid: 10 mM EGTA, 10 mM HEPES, 10 mM potassium chloride, 10 mM sodium chloride, 110 mM potassium fluoride (pH adjusted to 7.2 using potassium hydroxide).
[0140] Note: The osmotic pressure of the solution should be controlled between 280 and 300 mOsmol / kg. The solution needs to be filtered and stored at 4°C before use. 1.3 Solution of the compound to be tested
[0141] The test compound was dissolved in DMSO to prepare a stock solution with a final concentration of 10 mM. The stock solution was then serially diluted, and further diluted in extracellular fluid to obtain five test solutions with the desired final concentrations (µM): 30, 10, 3.33, 1.11, and 0.37. The concentration of DMSO in the test solutions was 0.1-0.3% (volume ratio). 1.4 Experimental Procedure
[0142] 1) The hKv1.3 current test method is as follows: Apply a depolarization command voltage for 2 seconds to depolarize the membrane potential from -80 mV to +50 mV, thereby allowing the hKv1.3 current to be observed. The peak value of the current is the magnitude of the hKv1.3 current.
[0143] 2) The hKv1.3 current used to detect the test compound was continuously recorded for 120 seconds before drug administration to assess the stability of the hKv1.3 current generated by the test cells. Only stable cells within the acceptable range of the evaluation criteria were allowed to proceed to the subsequent compound detection.
[0144] 3) Test of the inhibitory effect of the test compound on hKv1.3 current: First, the hKv1.3 current measured in extracellular fluid containing 0.1% DMSO was used as the baseline. After the hKv1.3 current stabilized for at least 5 minutes, the solution containing the test compound was perfused around the cells sequentially from low concentration to high concentration. After each perfusion, wait about 5 minutes to allow the compound to fully act on the cells and record the hKv1.3 current simultaneously. After the recorded current tended to stabilize, the last 5 hKv1.3 current values were recorded, and their average value was taken as the final current value at the specific concentration. After testing the compound, 100 µM carvedilol was added to the same cell to completely inhibit its current, serving as a positive control for that cell. 1.5 Data Analysis
[0145] Note: Data is output by PatchMaster software.
[0146] 1) After injecting blank solvent or compound gradient solution, the average of the 5 consecutive current values obtained after stabilization is taken as “current magnitude blank” and “current magnitude compound”, respectively.
[0147] The current suppression percentage is calculated using the following formula.
[0148] 2) The dose-response curve was fitted using Graphpad Prism 8.0 software and the IC50 value was calculated.
[0149] 3) The standard deviation range of the three groups of data is less than 15 (SD < 15). 1.6 Experimental Results
[0150] This experiment evaluated whether the compounds had potential inhibitory effects on the voltage-gated potassium ion channel hKv1.3 using a manual patch-clamp technique. The results are shown in Table 3. Table 3: IC50 of the inhibitory activity of the compounds of this invention on the hKv1.3 potassium ion channel. Example number IC50 (nM) Reference compound A 33.95 Reference compound B 10.03 Reference compound C 17.49 2 3.84 3 14.2 Note: Control compounds A, B and C are from WO2024088343A1.
[0151] The results showed that, compared with the control compound, the compound of the present invention had a significantly better inhibitory effect on the hKv1.3 potassium ion channel. Test Example 2: Manual patch-clamp method to detect the effect of the compound of the present invention on the hKv1.3 potassium ion channel (two concentration points) 1.1 Cells
[0152] The HEK293 cell line stably expressing the hKv1.3 ion channel used in this experiment was constructed by Kanglong Chemical. This cell line was cultured in a medium containing 90% DMEM (Thermo Fisher Scientific), 10% fetal bovine serum, 100 U / mL penicillin-streptomycin solution (Thermo Fisher Scientific), and 6 μg / mL puromycin (Sigma-Aldrich). Before the experiment, the cells were digested and seeded at a density of 5 × 10⁵ cells in 3.5 cm culture dishes containing coverslips for subsequent manual patch-clamp experiments. 1.2 Experimental Solutions
[0153] 1) Extracellular fluid: 132 mM sodium chloride, 4 mM potassium chloride, 3 mM calcium chloride, 0.5 mM magnesium chloride, 11.1 mM glucose and 10 mM HEPES (pH adjusted to 7.35 using sodium hydroxide).
[0154] 2) Intracellular fluid: 10 mM EGTA, 10 mM HEPES, 10 mM potassium chloride, 10 mM sodium chloride, 110 mM potassium fluoride (pH adjusted to 7.2 using potassium hydroxide).
[0155] Note: The osmotic pressure of the solution should be controlled between 280 and 300 mOsmol / kg. The solution needs to be filtered and stored at 4°C before use. 1.3 Solution of the compound to be tested
[0156] The test compound was dissolved in DMSO and prepared into a stock solution with a final concentration of 10 mM. The stock solution was then serially diluted, and further diluted into extracellular fluid to obtain two final concentrations of test solutions, namely (µM): 0.1 and 0.001 or 0.01 and 1. The concentration of DMSO in the test solutions was 0.1-0.3% (volume ratio). 1.4 Experimental Procedure
[0157] 1) The hKv1.3 current test method is as follows: Apply a depolarization command voltage for 2 seconds to depolarize the membrane potential from -80 mV to +50 mV, thereby allowing the hKv1.3 current to be observed. The peak value of the current is the magnitude of the hKv1.3 current.
[0158] 2) The hKv1.3 current used to detect the test compound was continuously recorded for 120 seconds before administration to assess the stability of the hKv1.3 current generated by the test cells. Only stable cells within the acceptable range of the evaluation criteria were allowed to proceed to the subsequent compound detection.
[0159] 3) Test of the inhibitory effect of the test compound on hKv1.3 current: First, the hKv1.3 current measured in extracellular fluid containing 0.1% DMSO was used as the baseline. After the hKv1.3 current stabilized for at least 5 minutes, the solution containing the test compound was sequentially perfused around the cells from low to high concentration. After each perfusion, approximately 5 minutes were allowed for the compound to fully act on the cells while the hKv1.3 current was recorded simultaneously. After the recorded current tended to stabilize, the last 5 hKv1.3 current values were recorded, and their average value was taken as the final current value at the specific concentration. After testing the compound, 100 µM carvedilol was added to the same cell to completely inhibit its current, serving as a positive control for that cell. 1.5 Data Analysis
[0160] Note: Data is output by PatchMaster software.
[0161] 1) After injecting blank solvent or compound gradient solution, the average of the 5 consecutive current values obtained after stabilization is calculated and used as “current magnitude blank” and “current magnitude compound”, respectively.
[0162] The current suppression percentage is calculated using the following formula.
[0163] 2) The dose-response curve was fitted using Graphpad Prism 8.0 software and the IC50 value was calculated.
[0164] 3) The standard deviation range of the three groups of data is less than 15 (SD < 15). 1.6 Experimental Results
[0165] This experiment evaluated whether the test compounds had potential inhibitory effects on the voltage-gated potassium ion channel hKv1.3 using a manual patch-clamp technique. The results are shown in Tables 4 and 5. Table 4 Inhibitory activity of the compounds of this invention on the hKv1.3 potassium ion channel (two concentration points, 0.001 µM / 0.1 µM) Example number % inhibition @ 0.001 µM % inhibition @ 0.1 µM 1 12.33 98.07 4 7.61 99.99 5 12.29 99.55 6 1.09 80.70 twenty two 17.6 96.45 25 5.39 86.68 28 0.11 65.1 30 15.95 76.47
[0166] The results show that the compounds of the present invention exhibit good inhibitory activity against the hKv1.3 potassium ion channel (1 nM < IC50 < 100 nM). Table 5 shows the inhibitory activity of the compounds of the present invention against the hKv1.3 potassium ion channel (two concentration points, 0.01 µM / 1 µM). Example number % inhibition @ 0.01 µM % inhibition @ 1 µM twenty one 78.82 100 twenty three 78.23 100.03
[0167] The results showed that the above-mentioned compound of the present invention had a good inhibitory effect on hKv1.3 potassium ion channel inhibitory activity (IC50 < 10 nM). Test Example 3: Rat Pharmacokinetic Study of the Compound of the Present Invention 1. Experimental Objective
[0168] Using SD rats as test animals, the drug concentration in plasma at different time points after injection of the compound of the present invention (Example 2) and control compounds 8343-01 and 8343-03 was determined by LC / MS / MS to study the pharmacokinetic characteristics of the compound of the present invention in mice. 2. Experimental Protocol
[0169] 2.1 Experimental drugs and animals; Control compound 8343-01, control compound 8343-03, Example 2; SD rats, male, 269-306 g, purchased from Vital River Laboratory Animal Technology Co., Ltd.
[0170] 2.2 Drug Preparation Intravenous Injection Group: Weigh an appropriate amount of drug, add DMA:30%solutol HS15:saline = 10:10:80 (v / v / v), and prepare a solution with a final concentration of 0.2 mg / mL; Oral Gavage Group: Weigh an appropriate amount of drug, add DMA:30%solutol HS15:saline = 10:10:80 (v / v / v), and prepare a solution with a final concentration of 1 mg / mL; 2.3 Drug Administration Twelve SD rats were administered the drug via intravenous injection or gavage, with three injections per group for a total of four groups. After fasting overnight, the rats were given the drug. They were fed four hours after administration. The dosages of each compound are shown in Table 6 below: Table 6 Dosages of Each Compound Compound numbering Administration method Dosage Dosage concentration Dosage volume Example 2 Intravenous administration 1 mg / kg 0.2 mg / mL 5 mL / kg Gavage administration 10 mg / kg 1 mg / mL 10 mL / kg Reference compound 8343-01 Intravenous administration 1 mg / kg 0.2 mg / mL 5 mL / kg Gavage administration 10 mg / kg 1 mg / mL 10 mL / kg Reference compound 8343-03 Intravenous administration 1 mg / kg 0.2 mg / mL 5 mL / kg Gavage administration 10 mg / kg 1 mg / mL 10 mL / kg 3. Operation
[0171] Blood samples of 150 μL were collected via the jugular sinus before administration and at 0.083, 0.25, 0.5, 1, 2, 4, 8, 10, and 24 hours after administration, and anticoagulated with EDTA-K2. After collection, blood samples were placed on ice and centrifuged within 30 minutes to separate the plasma (centrifugation conditions: 1500 g, 10 minutes). Collected plasma was stored at –40 to –20°C before analysis.
[0172] The levels of the target compounds in rat plasma after intravenous injection and gavage administration of different compounds were determined by LC-MS / MS. 4. Pharmacokinetic parameters results
[0173] Oral bioavailability is the percentage of AUC (area under the curve) after oral administration of an equal amount of drug and after intravenous administration of an equal amount of drug, calculated using the formula: %F = ÷ × 100%. Where AUC represents the area under the blood drug concentration-time curve, the subscripts ig and iv represent the oral gavage formulation and the intravenous injection formulation, respectively, and D represents the administered dose. The mouse pharmacokinetic parameters of the compounds of the present invention are shown in Table 7 below. Table 7 Mouse pharmacokinetic parameters of the compounds of the present invention Compound numbering Pharmacokinetic Experiment Administration method Dosage Blood drug concentration Cmax (ng / mL) Area of curve AUC 0-t (ng·h / mL) half life T1 / 2(h) Clearance rate CL ml . kg / min Distributed volume Vd ss (L / kg) Bioavailability F (%) Example 2 Intravenous administration 1 mg / kg 770 439 0.979 37.8 2.20 49.4% Gavage administration 10 mg / kg 725 2170 2.64 NA NA Reference compound B Intravenous administration 1 mg / kg 1490 318 0.91 51.7 1.92 16% Gavage administration 10 mg / kg 274 494 2.09 NA NA Reference compound C Intravenous administration 1 mg / kg 1203 794 0.64 1.28 1.19 18.7% Gavage administration 10 mg / kg 1006 1482 1.00 NA NA Note: N / A indicates no relevant results.
[0174] Conclusion: Compared with the control compound, the compound of the present invention in Example 2 has good pharmacokinetic absorption, higher bioavailability, and better pharmacokinetic properties. [Simplified Explanation of the Diagram]
[0069] None.
Claims
1. A compound of general formula (I) or a stereoisomer, tautomer, deuterated derivative or pharmaceutically acceptable salt thereof: wherein: L is selected from bond and -C (Raa Rbb); Raa and Rbb are each independently selected from hydrogen atom, hydroxyl and methyl; R1 is selected from hydrogen atom and C1-6 alkyl; R2, R3, R4, R5 are each independently selected from hydrogen atom, deuterium atom, halogen, C1-6 alkyl and halo-C1-6 alkyl; Ra is selected from hydrogen atom and C1-6 alkyl, wherein the C1-6 alkyl is optionally further substituted by one or more substituents selected from deuterium atom and halogen; Rb, Rc, Rd, Re are each independently selected from hydrogen atom, halogen, and C1-6 alkyl; RB is selected from hydrogen atom; RA is selected from hydroxyl, C1-6 alkyl, C2-6 alkenyl, 3-12 membered heterocyclic group, C6-10 aryl, 5-6 membered heteroaryl; wherein the C1-6 alkyl, C2-6 alkenyl, 3-12 membered heterocyclic group, C6-10 aryl, 5-6 membered heteroaryl is optionally further substituted by one or more RAA; RAAs may be identical or different, each independently selected from hydroxyl, halogen, and C1-6 alkyl; wherein the C1-6 alkyl is optionally further substituted by one or more substituents selected from halogen; or, two RAAs together with the same carbon atom to which they are attached form a C3-6 cycloalkyl, 3-12 membered heterocyclic group; wherein the C3-6 cycloalkyl or 3-12 membered heterocyclic group is optionally further substituted by one or more substituents selected from hydroxyl, halogen, and C1-6 alkyl; provided that compounds of general formula (I) do not include the following structures: and.
2. The compound as claimed in claim 1, or a stereoisomer, tautomer, deuterated derivative or pharmaceutically acceptable salt thereof, wherein R1 is a hydrogen atom.
3. The compound or its stereoisomers, tautomers, deuterated derivatives or pharmaceutically acceptable salts as claimed in claim 1, wherein the compound or its stereoisomers, tautomers, deuterated derivatives or pharmaceutically acceptable salts are of general formula (II): wherein: R2 is selected from hydrogen atoms and halogens; R3 is selected from C1-4 alkyl groups and halogens; R4 is selected from hydrogen atoms, C1-4 alkyl groups and halogens; Rb, Rc, Rd, and Re are selected from hydrogen atoms; R5 is selected from hydrogen atoms, deuterium atoms, and halogens; L, Ra, RA, and RB are defined as described in claim 1.
4. The compound as claimed in claim 3, or a stereoisomer, tautomer, deuterated derivative or pharmaceutically acceptable salt thereof, wherein the halogen in R2 is chlorine.
5. The compound as claimed in claim 3, or a stereoisomer, tautomer, deuterated derivative or pharmaceutically acceptable salt thereof, wherein the halogen in R3 is chlorine.
6. The compound as claimed in claim 3, or a stereoisomer, tautomer, deuterated derivative or pharmaceutically acceptable salt thereof, wherein the C1-4 alkyl group in R3 is methyl.
7. The compound as claimed in claim 3, or a stereoisomer, tautomer, deuterated derivative or pharmaceutically acceptable salt thereof, wherein the halogen in R4 is chlorine.
8. The compound as claimed in claim 3, or a stereoisomer, tautomer, deuterated derivative or pharmaceutically acceptable salt thereof, wherein the C1-4 alkyl group in R4 is methyl.
9. The compound or its stereoisomers, tautomers, deuterated derivatives or pharmaceutically acceptable salts as claimed in claim 1, wherein the compound or its stereoisomers, tautomers, deuterated derivatives or pharmaceutically acceptable salts are of general formula (III-1) or (III-2): wherein: R3 is selected from methyl and chlorine; R4 is selected from methyl and chlorine; R5 is selected from hydrogen atom, deuterium atom, chlorine, fluorine; Rb, Rc, Rd, Re are selected from hydrogen atom; L, Ra, RA and RB are defined as described in claim 1.
10. The compound of claim 1 or a stereoisomer, tautomer, deuterated derivative or pharmaceutically acceptable salt thereof, wherein Rb, Rc, Rd, Re are hydrogen atoms, Ra is selected from hydrogen atoms or C1-6 alkyl groups, wherein the C1-6 alkyl group is optionally further substituted with one or more deuterium atoms.
11. The compound as claimed in claim 10, or a stereoisomer, tautomer, deuterated derivative or pharmaceutically acceptable salt thereof, wherein Ra is selected from hydrogen atom, methyl, deuterated methyl and ethyl.
12. The compound or its stereoisomers, tautomers, deuterated derivatives or pharmaceutically acceptable salts as claimed in claim 1, wherein the compound or its stereoisomers, tautomers, deuterated derivatives or pharmaceutically acceptable salts are of general formula (IV-1) or (IV-3): wherein: R3 is independently selected from methyl or chlorine; R4 is independently selected from methyl or chlorine; R5 is selected from hydrogen, deuterium, fluorine or chlorine; Ra is selected from hydrogen, methyl, deuterated methyl, or ethyl; L and RA are defined as described in claim 1.
13. The compound as claimed in claim 1, or a stereoisomer, tautomer, deuterated derivative or pharmaceutically acceptable salt thereof, wherein L is selected from the group consisting of a bond, -CH2-, and -C(CH3)2-.
14. The compound of claim 1 or its stereoisomers, tautomers, deuterated derivatives or pharmaceutically acceptable salts thereof, wherein RA is selected from hydroxyl, phenyl, C1-6 alkyl, C2-6 alkenyl, 3-12 heterocyclic, and 5-6 heteroaryl, wherein the phenyl, C1-6 alkyl, C2-6 alkenyl, 3-12 heterocyclic, or 5-6 heteroaryl may optionally be further substituted by one or more RAAs; the RAAs may be the same or different and are each independently selected from halogen, hydroxyl, and C1-6 alkyl; or, two RAAs together with the same carbon atom to which they are attached form a C3-6 cycloalkyl, 3-12 heterocyclic group.
15. The compound as claimed in claim 13, or a stereoisomer, tautomer, deuterated form thereof, or a pharmaceutically acceptable salt thereof, wherein the group is selected from the following: ethyl, vinyl, and .
16. The compound as claimed in claim 1, or a stereoisomer, tautomer, deuterated derivative or pharmaceutically acceptable salt thereof, wherein the compound is selected from: and.
17. A pharmaceutical composition comprising the compound as claimed in claim 1, or a stereoisomer, tautomer, deuterated form thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
18. Use of a compound as claimed in any one of claims 1 to 16, or a stereoisomer, tautomer, deuterated form thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition as claimed in claim 17, in the preparation of a Kv1.3 potassium channel inhibitor.
19. Use of a compound, stereoisomer, tautomer, deuterated form or pharmaceutically acceptable salt thereof, or pharmaceutical composition as claimed in claim 17, in the preparation of a medicament for treating diseases mediated by Kv1.3 potassium channels.
20. The use as described in claim 19, wherein, The diseases mediated by the Kv1.3 potassium channel are autoimmune diseases.
21. The use as described in claim 20, wherein, The autoimmune diseases mentioned are selected from rheumatoid arthritis, psoriasis, systemic lupus erythematosus, atopic dermatitis, ulcerative colitis, Crohn's disease, type I diabetes, obesity, hypertension, transplant rejection, multiple sclerosis, periodontitis, and chronic kidney disease.
22. Use of a compound as claimed in any one of claims 1 to 16, or a stereoisomer, tautomer, deuterated form thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition as claimed in claim 17, in the preparation of a medicament for treating autoimmune diseases.
23. The use as described in claim 22, wherein, The autoimmune diseases mentioned are selected from rheumatoid arthritis, psoriasis, systemic lupus erythematosus, atopic dermatitis, ulcerative colitis, Crohn's disease, type I diabetes, obesity, hypertension, transplant rejection, multiple sclerosis, periodontitis, and chronic kidney disease.
Citation Information
Patent Citations
Aryl heterocyclic compounds as Kv1.3 potassium Shaker channel blockers
CN114746151A
Aryl heterobicyclic compounds as Kv1.3 potassium SHAKER channel blockers
CN114828963A
Aryl heterocyclic Kv1.3 inhibitor as well as preparation method and application thereof
CN117946111A
